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While prior studies have focused on naïve (CD45RA+CD27+) and early stage 
memory (CD45RA-CD27+) CD8+ T cells, late memory CD8+ T cells (CD45RA+CD27) 
have received less interest because this subset of T cells is generally recognized as effectors, 
which produce IFNγ (but no IL-2) and perforin.  However, multiple studies suggest that late 
memory CD8+ T cells may provide inadequate protection in infectious diseases and cancer 
models.  
To better understand the unique function of late memory CD8+ T cells, I optimized 
multi-color flow cytometry techniques to assess the cytokine production of each human 
CD8+ T cell maturation subset.  I demonstrated that late memory CD8+ T cells are the 
predominant producer of CC chemokines (e.g. MIP-1β), but rarely produce IL-2; therefore 
they do not co-produce IL-2/IFNγ (polyfunctionality), which has been shown to be critical 
for protective immunity against chronic viral infection.  These data suggest that late memory 
CD8+ T cells are not just cytotoxic effectors, but may have unique functional properties.   
Determining the molecular signature of each CD8+ T cell maturation subset will 
help characterize the role of late memory CD8+ T cells.  Prior studies suggest that ERK1 
and ERK2 play a role in cytokine production including IL-2 in T cells.  Therefore, I tested 
 vi 
whether differential expression of ERK1 and ERK2 in CD8+ T cell maturation subsets 
contributes to their functional signature by a novel flow cytometry technique.  I found that 
the expression of total ERK1, but not ERK2, is significantly diminished in late memory 
CD8+ T cells and that ERK1 expression is strongly associated with IL-2 production and 
CD28 expression.  I also found that IL-2 production is increased in late memory CD8+ T 
cells by over-expressing ERK1.  Collectively, these data suggest that ERK1 is required for 
IL-2 production in human CD8+ T cells. 
In summary, this dissertation demonstrated that ERK1 is down-regulated in human 
late memory CD8+ T cells, leading to decreased production of IL-2.  The data in this 
dissertation also suggested that the functional heterogeneity in human CD8+ T cell 
maturation subsets results from their differential ERK1 expression.   
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CHAPTER 1 
INTRODUCTION 
 
 2 
  In murine models, many investigators have studied memory T cell generation, 
genetic and epigenetic regulation of T cell maturation, the relationship between memory T 
cell generation and protective immunity, and the differential function of T cell memory 
subsets.  However, much less is known about how those findings apply to human T cells. 
Despite inherent limitations of human immunology studies, recent technical advances have 
better enabled us to investigate the function of memory T cells and the relationship between 
functional heterogeneity of T cell maturation subsets and control of pathogens (e.g. viruses) 
and cancers.  To better understand human T cell memory, we and others are examining the 
intrinsic functions of T cell maturation subsets defined by surrogate surface markers, and the 
underlying molecular mechanisms generating this functional heterogeneity.  A better 
understanding of how T cell maturation subsets confer protective immunity will allow us to 
improve immune modulations, including immunization and adoptive cellular therapies.  I 
have focused on the functional and molecular signatures of CD8+ T cell maturation subsets 
and their relationships in this dissertation, because (a) CD8+ T cells are critical effectors in 
the setting of infections and cancer; (b) there are still controversial studies about function, 
terminologies and markers of CD4+ T cell lineage (e.g. central memory vs. effector 
memory, Th1 vs Th2 etc.); (c) CD4+ T cells are less optimal for studies of late memory T 
cells due to lower cell numbers in this stage relative to the CD8+ compartment.  To 
formulate the hypothesis, I described the current opinions about memory T cell generation in 
mouse models, cross-sectional assessment of human memory T cells, functional signature of 
human memory T cells and differential T cell receptor (TCR) signal transduction in memory 
T cells in Chapter 1.  More specifically, the relationship between polyfunctionality of 
memory T cells and protective immunity, and the role of MAP kinase pathways in T cells 
were described in Chapter 1.   
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IMMUNOLOGICAL MEMORY 
Immunological memory is one essential characteristic of adaptive immunity.  Once 
the initial response to a pathogen is imprinted in a subset of immune cells, subsequent 
exposure to the pathogen previously encountered causes faster and more robust immune 
responses to clear infection.  With two key properties (longevity and proliferation potential), 
both humoral and cellular immunity are important players in immunological memory (1).   
A key player in humoral immunity, a B cell recognizes an virus and phagocytoses 
the viral particle (2).  The internalized virus particle is degraded into peptides and the 
peptides are presented on the cell surface by MHC class II molecules.  Helper T cells 
(mostly, Th2 subset) activate B cells through co-stimulation (e.g. via CD40-CD40L 
interaction) and cytokines (e.g. IL-4) to make antibodies that recognize viral proteins.  
Humoral immunity to infections lasts for decades in humans and in mice.  Humoal immunity 
via prolonged antibody generation provides the first line of defense against pathogens 
through neutralization, opsonization and complement activation.  The maintenance of high 
titers of antibody in serum is critical to humoral immunity (3).  For the maintenance of high 
serum antibody levels, long-lived plasma cells constitutively produce antibody, and memory 
B cells remains differentiated into plasma cells.  Otherwise, naïve B cells must become 
activated and differentiated to replace dying plasma cells.   
 
T CELL MEMORY 
 In contrast to humoral immunity, naïve T cells are activated in secondary lymphoid 
organs by antigens presented on MHC class I/II molecules on antigen-presenting cells 
(APC) along with co-stimulation, and then proliferate into numerous daughter cells (more 
than 10,000 progenies) over the period of 5~8 days and differentiate into effector cells.   
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Effector cells produce cytotoxic molecules (e.g. perforin and granzymes) and effector 
cytokines (e.g. IL-2, IFNγ and TNFα) for effective pathogen clearance.  The clearance of 
infection follows a contraction phase, leading to apoptosis of ~90% of primed T cells by 
activation-induced cell death, to allow for response to new pathogens and to minimize 
autoimmune diseases, which could occur in the host with persistence of activated T cells.  
Despite this extensive apoptosis during the contraction phase,  ~10% of activated cells 
become memory T cells (4).   
Since Ahmed and Gray proposed that multiple models may explain how memory and 
effector T cells are related and how naïve cells differentiate to memory or effector cells (1), 
memory T cell differentiation and maintenance have been extensively studied (2, 3, 5-8).  
One of the most conventional models, supporting linear differentiation, proposes that 
antigens drive activation and expansion of naïve cells, called the effector phase (9, 10).  
Effector T cells either become terminally differentiated T cells or mature into effector 
memory T cells that are characterized by low levels of CD62L, and CC-chemokine receptor 
7 (CCR7) and are replication incompetent.  Effector memory T cells can differentiate into 
central memory T cells that express CCR7 and CD62L, and they reside in lymphoid tissues 
(4, 11-15).  More recently, Sarkar and Ahmed demonstrated that naïve CD8+ T cells 
differentiate into effector cells and it is from these effector cells that memory cells are 
eventually generated after antigen clearance (4).   
Although several lines of evidence described above support that memory T cells 
emerge from activated effector T cells, recent studies in both murine and human models 
suggest that memory cells may not pass through an effector phase (16-21).  A bifurcation 
model proposed by Chang et al., suggests that one T cell primed by an antigen divides into 
two daughter cells with distinct phenotypes (22).  For instance, by differential polarization 
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of cellular components (e.g. co-receptors and signaling molecules) between the two daughter 
cells of primed naïve T cells, the distal daughter cell differentiates into central memory T 
cells, while the proximal daughter cell matures into effector memory/effector T phenotype 
(15, 22-24).  Stemberger et al. reinforced the bifurcation model with their studies, 
suggesting from a single adoptively transferred naïve CD8+ T cell, diverse maturation 
phenotypes of T cells can be generated (25). 
As described above, acute antigen exposure induces the evolvement of phenotypes 
and function of memory T cell populations, and it has also been suggested that cytokine 
exposure contributes to it (5, 26-28).  In addition, several studies suggest that cytokine-
driven proliferation is critical to maintain the numbers of memory T cells after acute 
infection (29-32), while persistent antigen exposure is not necessarily required for the 
maintenance(33).  Under circumstances where acute infection is cleared, memory T cells are 
maintained by the common γ-chain receptor cytokines (e.g. IL-7 and IL-15).  IL-7 and IL-15 
seem to provide survival and proliferation signals to memory CD8+ T cells, respectively 
(29-32).  It has been suggested that this basal level of proliferation driven by cytokine must 
be balanced by a similar rate of apoptosis (memory turnover), leading to maintaining the 
size of the memory T cell pool (34).  Moreover, through cytokine-driven memory turnover, 
the phenotypes of CD8+ memory T cell subsets are directed to central memory and effector 
memory, and the cells continue to maintain polyfunctionality (34). 
In contrast to acute antigen exposure models (linear, bifurcation) and the memory 
maintenance model (cytokine-driven), chronic infections induce substantial alterations in the 
phenotype and function of memory CD8+ T cells (35, 36).  This could result in the 
exhaustion or impairment of their effector functions (37).  Recently, several studies 
examined the underlying mechanisms of immune exhaustion during chronic infections.  
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Barber et al. and Freeman et al., demonstrated that the expression of Programmed cell death 
1 (PD-1) of memory CD8+ T cells decreased their functionality in persistently infected mice 
(38, 39).  Velu et al. also demonstrated that immune responses during a chronic simian 
immunodeficiency virus (SIV) infection, are restored by blocking the engagement between 
PD-1 and PD-1 ligand (40).  In addition, Brooks et al. and Ejrnaes et al. respectively showed 
that IL-10 impairs T cell responses during chronic viral infection, while IL-10 blockades 
restore anti-viral immunity (41, 42).  More importantly, maintenance of memory CD8+ T 
cells during chronic infection in contrast to acute infection requires the interaction of T cells 
with viral peptides, not with inflammatory cytokines such as IL-7 and IL-15 (43-46).  Thus, 
continuous exposure to antigen forces CD8+ T cells to extensively proliferate, leading to a 
signature of exhaustion, such as decreasing cell numbers and gradual lose of their ability to 
produce IL-2.   
Taken together, there are many unresolved questions related to T cell memory.  
Outstanding issues include: (a) which murine models best approximate human memory T 
cell generation, (b) whether cytokine-driven T cell maintenance in murine studies are similar 
in humans, (c) if the exhausted T cell population following persistent infection in mice is 
identical to one certain T cell subsets in humans (e.g. effector, CD45RA revertant, late 
memory, or terminally differentiated T cells). 
 
CROSS-SECTIONAL ASSESSMENT OF HUMAN MEMORY T CELLS  
We have been studying CD8+ T cell responses to virus and T cell differentiation via 
a longitudinal analysis in murine models.  To extend our understanding in murine models, 
Picher et al. demonstrated in nonhuman primates that Bromodeoxyuridine (BrdU)-labeled 
antigen-specific T cells in SIV-infected monkeys progressively differentiate from 
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CD28+CCR7+CCR5-, to CD28+CCR7-CCR5- or CD28+CCR7+CCR5+, and then to 
CD28+CCR7-CCR5+ (effector memory); CD28- T cells in this model seem to be 
terminally-differentiated or end-staged cells (47).   A longitudinal analysis recently done by 
Miller et al., suggests that human memory CD8+ T cell responses to smallpox and yellow 
fever vaccines are similar to a linear differentiation model in mice (48).  However, in 
humans, we still have had to rely primarily on cross-sectional assessments of immune 
responses against chronic infections, such as human immunodeficiency virus (HIV), 
cytomegalovirus (CMV), hepatitis C virus (HCV) and Epstein-Barr virus (EBV) to 
characterize T cell differentiation (49-57).  One inherent problem is the need to use 
surrogate markers of naïve and memory T cell differentiation; variations in subsets defined 
by such surface markers have led to the lack of a consistent language used to define 
maturation stages.  This has led to the use of semantic terms (e.g., central, effector and late 
memory cells) that are often inconsistent between studies, in part due to varying marker 
combinations or functional measures.  Even basic terminologies have different definitions in 
the literature.  In general, memory T cells are referred to as cells that have been primed with 
an antigen.  Activated T cells are sometimes called memory T cells because they are no 
longer naïve.  Effector T cells, more traditionally, are defined as cells which exist during the 
primary or secondary phases of an infection.  But many researchers regard effectors as cells 
which contain effector functions (e.g. perforin production) ex vivo (58).  Despite these 
limitations and the inconsistencies between studies due to inconsistent terminologies, we are 
beginning to better understand the consequences of T cell differentiation, especially as more 
advanced technological approaches to assess phenotypic and functional characteristics of 
fine T cell subsets have been developed. 
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   The rapid advancement of flow cytometry has facilitated a better understanding of 
cell surface markers associated with human T cell maturation (Figure 1).  Initially, CD45R 
isoforms were found to demarcate naïve (RA+/RO-) and memory (RA-/RO+) cells (59, 60).  
However, with the demonstration by Sprent and others that antigen-primed CD45RO+ cells 
could revert to CD45RA+ T cells (61-63), additional markers including CCR7 were 
suggested as a way to divide RA-/RO+ memory cells into earlier (“central” cells, capable of 
lymph node homing) and later “effector” memory cells (64).  Additional studies 
demonstrated that down-regulation of CD27 and CD28 could also be used to define CD4+ 
and CD8+ T cell maturation stages (51, 65-68).  In addition, it has been shown that CD57 
expression defines a subset of terminal memory CD8+ T cells characterized by replicative 
senescence (69).  Telomere length has also been shown to be different in T cell maturation 
subsets, suggesting that each maturation subsets have different cell division histories (70-
72).  Interestingly, the expression of CD57 revealed an inverse correlation with telomere 
length, suggesting that CD57+ T cells have divided more than other subsets (69, 71).   Other 
markers, including CD62L, CD11a, HLA-DR and CD95 have been used to better 
distinguish naive and memory subsets (73-77).  
In contrast to CD8+ T cells, the phenotype and functionality of CD4+ T cell 
maturation subsets, remain relatively ambiguous (58).  Earlier studies suggest that the 
expression of chemokine receptors in CD4+ T cells can delineate Th1 and Th2 responses 
(e.g. CCR5 and CXCR3: Th1 cytokine, CCR3, CCR4, and chemoattractant receptor-
homologous molecule expressed on Th2 (CRTh2): Th2 cytokine) (78).  Moreover, the 
markers used to define the CD8+ T cell populations (e.g. CD45RA, CCR7, CD27, CD28) 
have also been adapted to discriminate several CD4+ T cell subsets.  Surprisingly, using  
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Figure 1. More than two surface markers delineate human naïve and memory CD8+ T 
cell subsets.  CD45RA and CD27 can define naïve CD8+ T cells (CD45RA+CD27+) up to 
90% and three other memory CD8+ T cell subsets (early memory (M1): CD45RA-CD27+, 
intermediate memory (M2): CD45RA-CD27-, late memory (M3): CD45RA+CD27-).   
 
Nature Publishing Group (NPG) granted permission to reproduce and modify the Figure in 
the paper published (McMichael AJ and Rowland-Jones SL. Nature, 2001 Apr 19; 
410(6831):980-7). 
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these markers, functional and phenotypic similarities between T cell maturation subsets of 
CD4 and CD8 lineages have been found (68, 79, 80).  
These studies support the view that the use of at least two surface phenotypic 
markers (e.g., CD45RA and CD27) is required to divide cells into earlier and later stages of 
the T cell maturation spectrum (Figure 1).  However, results using all the surface markers 
together, suggest that while all the surface markers can precisely identify naïve T cells 
(CD45RA+CCR7+CD27+CD28+CD62L+), the combination of these markers gives rise to 
numerous subpopulations of T cell maturation subsets.  This could be a reflection of the 
heterogeneity of CD4+ and CD8+ T cell maturation subsets.  However, it is important to 
realize that the expression of numerous markers considerably overlap with each other (69, 
81-86).  Consistent with overlapping markers, general patterns of phenotype and functional 
attributes clearly exist within the heterogeneous T cell populations.   
 
FUNCTIONAL SIGNATURE IN HUMAN MEMORY T CELL SUBSETS 
Far fewer studies have focused on the relationship of maturation stage with 
functional signature, as defined by the combination of cytokines produced by T cells.  
Hamann et al. demonstrated that CD8+CD45RA+CD27- cells do not secrete IL-2, but 
produce IFNγ and TNFα, while CD45RA-CD45RO+ cells express higher levels of CD95 
(Fas) and the integrin family members CD11a, CD18, CD29, CD49d, and CD49e, compared 
with naive CD8+ T cells, and are able to produce multiple cytokines including IL-2 and 
IFNγ (51).  Sallusto and Lanzavecchia showed that CD4+ central memory T cells secrete 
more IL-2, but less IFNγ than CD4+ effector memory T cells (64).  Sandberg and colleagues 
found that IL-2 was not co-produced in perforin-positive T cells in response to 
staphylococcal enterotoxin B (SEB) and perforin-positive T cells were almost exclusively 
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CD57+ and CD45RA high; differential cytokine production occurred within surface marker-
defined CD8+ T cell maturation stages (87).  Tomiyama et al. also demonstrated that 
perforin expression, cytotoxic activity and CCR5 expression are different in the 
subpopulations (CD27+CD28+, CD27+CD28-, CD27-CD28-) of CD45RA-CD8+ T cells 
(85).  In addition, Bratke et al. and Takata et al., respectively showed the differential 
production of granzymes in CD8+ T cell maturation subsets.  These data suggest that 
granzyme K production occurs in CCR7-CD27+CD28+ CD8+ T cells, whereas granzyme B 
is produced predominantly in CCR7-CD27-CD28- CD8+ T cells (88, 89).  Furthermore, 
CD56, CD11a, CD11b, CCR5, KLGR1 and IL-7 receptor alpha have been used to define 
CD8+ T cell maturation subsets and demonstrate the relationship between their expression 
and function (90). 
While many similarities have been observed between CD8+ and CD4+ T cell 
subpopulations defined by CD45RA, CCR7, CD28 and CD27, in terms of functional 
attributes and phenotypes, the expression of chemokine receptor has been used to define 
novel CD4+ T cell subsets.  Recently, the expression of CCR6 and CCR4 has been 
demonstrated to identify a Th17 subset in humans (91).  In contrast, the expression of 
CCR6, CXCR3, IL-23R and the transcription factor ROR gamma t, delineate populations 
consisting of Th1 cells and Th17/Th1 cells producing both IFNγ and IL-17 (91, 92).  
Despite extensive efforts to define the association between the phenotypes and the 
functional attributes of T cell subsets, the association is less obvious in virus-specific T cell 
responses because virus-specific T cells tend to be concentrated within certain T cell 
subsets.  For instance, two independent studies in HIV-infected adults suggest that more 
than 50% of IL-2-producing CD4+ T cells specific for viruses associated with persistent 
infection (e.g. CMV, influenza virus, EBV, HSV) are in the effector memory subset (93, 
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94).  Similarly, in mice infected with Leishmania major or in humans infected with vaccinia 
virus, IL-2 was produced predominantly in effector memory CD4+ T cells (CCR7-) (95, 96).  
Duvall et al. demonstrated that in HIV-2 specific CD8+ T cells, there was no significant 
difference in terms of functional profiles in T cell maturation subsets (97).  These findings 
suggest that the type of infection or the duration of antigen exposure may also determine 
which T cell maturation subsets predominantly produce IL-2. 
Despite all of the attempts to determine the relationship between T cell maturation 
subsets and function, few studies have analyzed T cells following activation with multiple 
stimuli and/or examined the production of multiple cytokines in a systematic fashion to 
determine the intrinsic capacity of each T cell maturation subset, as is now possible using 
modern cytometric approaches. 
 
POLYFUNCTIONAL T CELLS AND PROTECTIVE IMMUNITY  
Although traditional studies focused on the magnitude of T cell responses, it is 
evident that T cell quality is also important in chronic viral infection and vaccination.  The 
correlation between T cell quality (e.g. polyfunctionality) and clinical outcome has been 
studied in HIV models.  Earlier studies analyzing dual cytokine production (IL-2 and IFNγ) 
by CD4+ T cells from patients infected with HIV, showed that long-term non-progressors 
(LTNPs) or patients treated with anti-viral therapy, had increased frequencies of CD4+ T 
cells producing IL-2 only or co-producing both IL-2 and IFNγ, while CD4+ T cells in 
progressors produced IFNγ alone (98-101).  Additional studies suggest that ~50% of the 
total HIV-specific T cell responses from LTNPs or patients on anti-retroviral treatment are 
polyfunctional (e.g. IL-2+IFNγ+TNFα+ or IL-2+IFNγ+), while cytokine production pattern 
in patients with high viral loads was skewed to IFNγ only (93, 102).  Consistent results were 
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reported in the setting of infections with HCV (103), Mycobacterium tuberculosis (104) and 
CMV (105).  These studies suggest that polyfunctional CD4+ T cells that produce two or 
more cytokines are associated with viral clearance or control of viral reactivation (Figure 2). 
The quality of CD8+ T cell responses has been investigated in the context of 
protective immunity against viral infections and cancers.  Migueles et al. demonstrated that 
HIV-specific CD8+ T cells in HIV-1 infected LTNPs showed an early memory phenotype 
(CD45RO+CD28+CD27+), which maintained their proliferative potential following in vitro 
stimulation (106).  Duvall, Koup and colleagues showed that cytokine signature of HIV-2 
specific T cells is more polyfunctional than that of HIV-1 specific T cells, which can explain 
delayed disease progression in patients infected with HIV-2 (97).  In a murine melanoma 
immunotherapy model, Gattinoni et al. demonstrated that fully differentiated melanoma-
specific effector cells had impaired antitumor efficacy despite their ability to secrete 
abundant amounts of IFNγ and perforin, while early memory cells with identical specificity 
effectively controlled tumor growth (107).  Recently, Betts et al. found there was a 
significantly higher frequency of CD8+ T cells that produce four or five effector molecules 
simultaneously (IFNγ+TNFα+MIP1β+CD107+IL-2-, IFNγ+TNFα+MIP1β+CD107+IL-2+) 
in LTNPs, compared with CD8+ T cells from progressors (108).  All these studies suggest 
that polyfunctional CD8+ T cells or early memory CD8+ T cells are strongly associated with 
protective immunity against viruses and cancer cells. 
Several speculative explanations exist on why polyfunctional T cells are optimal for 
protective immunity (109).  In mice vaccinated with Leishmania major, there was a 
progressive increase in the mean fluorescence intensity (MFI) of IL-2, IFNγ, and TNFα in 
CD4+ T cells that produce all three cytokines together, compared with dual- or single- 
cytokine-producing cells (95).  For example, polyfunctional CD4+ T cells made up to ten  
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Figure 2. Polyfunctional T cells are associated with effective protective immunity.  
Polyfunctional T cells exhibit better T cell quality because polyfunctional CD4+ T cells 
making more cytokine on a per-cell basis than monofunctional CD4+ T cells.  
Simultaneous secretion of both IFNγ and TNFα from one polyfunctional T cell may 
mediate more efficient killing compared with either cytokine alone.  Secretion of IL-2 
from polyfunctional T cells promotes the expansion of T cells in an autocrine or paracrine 
manner, which could enhance CD8+ T cells memory maintenance.  
 
John Wiley and Sons granted permission to reproduce and modify the Figure in the paper 
published (Harari A. et al. Immunol Rev, 2006 Jun;211:236-54). 
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times more IFNγ on a per-cell basis than single-cytokine producing CD4+ T cells.  These 
findings were also confirmed by ELISPOT (95).  Similar results were reported in a study 
demonstrating the relationship between polyfunctionality of T cells and the effect of 
vaccination in humans immunized with the smallpox vaccine virus (102) or modified 
vaccinia virus Ankara (96).  Secondly, the co-production of both IFNγ and TNFα from one 
cell may mediate better cytotoxicity compared with either cytokine alone (110, 111).  
Finally, IL-2 from polyfunctional T cells induces the proliferation of T cells in an autocrine 
or paracrine fashion, which could help T cell memory maintenance (112). 
Taken together, polyfunctional CD4+ and CD8+ T cells are associated with better 
responses to vaccination and protective immunity against chronic viral infections and 
cancers.  Therefore, it is important to know which maturation stages of T cells are more 
polyfunctional, what mechanisms (e.g. signal transduction) lead to polyfunctionality in 
memory T cells and how to boost the polyfunctionality of memory T cells to better induece 
and maintain protective immunity.  
 
DIFFERENTIAL SIGNAL TRANSDUCTION IN T CELL MATURATION 
SUBSETS 
For T cells to be activated, the T cell receptor (TCR) binds with a ligand on MHC 
class molecule of an antigen presenting cell (APC).  It leads to activation of Lck and Fyn, 
which in turn phosphorylate immunoreceptor tyrosine-based activation motifs (ITAMs) 
within the cytoplasmic domain of CD3ζ chain.  The phosphorylated ITAMs provide docking 
sites for ZAP-70.  ZAP-70 activates adaptor molecules such as LAT and SLP-76, which 
subsequently activate phospholipase Cγ1 (PLCγ1).  PLCγ1 generates inositol 1, 4, 5-
triphosphate (IP3) and diacylglycerol (DAG), second messengers involved in intracellular 
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Ca2+ release and protein kinase C (PKC) activation, respectively (113) (Figure 3).  These 
pathways are crucial for cytokine production, proliferation and differentiation in T cells 
through transcription factors (NFAT and AP-1).   
Although recent studies have better characterized human T cell maturation, less is 
known about how signal transduction is associated with functional heterogeneity of T cell 
maturation subsets.  Farber et al. demonstrated murine CD4+ memory T cells produce fewer 
species of tyrosine-phosphorylated substrates than naïve T cells and fail to phophorylate 
ZAP-70 (114).  Hall and coworkers showed that human CD45RA+ CD4+ T cells were more 
active in TCR-dependent tyrosine phosphorylation, especially CD3ζ and ZAP-70 than 
human CD45RO+ CD4+T cells though the total expression levels were equivalent between 
the two subsets (115).  Krishnan et al. demonstrated that human effector CD4+T cells 
generated in vitro by polyclonal activation exhibit elevated levels of intracellular tyrosine 
phosphorylation concomitant with reduced expression of CD3ζ and CD3ε (116).  Hussain et 
al. explained the more rapid responses of CD4+ effector T cells with higher SLP-76 
expression, compared with CD4+ memory T cells in a murine model (117).  More recently, 
Kersh et al. showed that murine memory CD8+T cells do not increase TCR sensitivity nor 
initial CD3 signaling events, yet have more extensive lipid rafts to more efficiently induce 
phosphorylation of LAT and its downstream molecules than naïve and effector CD8+ T cells 
(118).   
Additionally, to define the distinct molecular signature of each T cell maturation 
subset, several investigators performed high-throughput genomic studies in mouse and 
human T cell maturation subsets.   Holmes et al. showed that human naïve CD8+ T cells 
(CD45RA+CD27+) have distinct gene expression patterns from the effector subset 
(CD45RA+CD27-) (119).  Willinger and colleagues also demonstrated that human effector  
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Figure 3. Schematic view of T cell signaling pathways.  MAP kinase pathways are 
critical for T cell activation, proliferation/differentiation and cytokine production. 
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memory CD8+ T cells (CD45RA-CCR7-) express genes encoding lytic granule proteins 
(e.g. granzyme A, B, perforin etc.), genes involved in protein sorting to granules and granule 
transport/exocytosis and genes encoding IFNγ and chemokines (e.g. CCL5 (RANTES)), 
whereas central memory CD8+ T cells (CD45RA-CCR7+) are characterized by high basal 
and cytokine-induced STAT5 phosphorylation (120).  Recently, Appay et al. revealed that 
CD4+ and CD8+ T cell gene expression is very similar depending on maturation stages (80).  
On the other hand, Kaech and Ahmed demonstrated in a murine model, that the mRNA level 
of genes associated with TCR signaling, intracellular Ca2+ signaling, and cytokine signaling, 
are increased in effector CD8+ T cells, leading to enhancement of signaling pathways and 
faster responses to antigens (121).  They also found that other genes involved in cytokine 
production (p38, JNK etc.) and cell cycles (cyclin E1, E2 and B1) are up-regulated in 
memory CD8+ T cells.  Their data also demonstrated that mRNAs of effector molecules 
(e.g. granzyme B and IFNγ) are constitutively expressed, which facilitates rapid recall 
responses in memory CD8+ T cells.   
Despite all these studies, it remains to be elucidated (a) which genes or pathways 
dictate the production of effector molecules such as cytokines and chemokines, and cellular 
proliferation and migration in T cell maturation subsets; (b) which genes regulate T cell 
maturation. 
 
THE ROLE OF MAPK PATHWAYS IN POST-THYMIC T CELLS 
Of the TCR signaling molecules, mitogen-activated protein (MAP) kinases have 
been extensively studied in T cells.  Three key MAP kinase pathways have been investigated 
in mammalian cells.  These are the extracellular signal-regulated kinase (ERK) (122, 123), 
the Jun NH2-terminal kinase (JNK) (124-126), and the p38 kinase (127-129).  In addition to 
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the critical roles of these three MAP kinase pathways in early thymocyte development (130-
136), positive/negative selection and lineage commitment of thymocytes (137-143), these 
pathways have been reported to play an important role in IL-2 production in peripheral T 
cells (144-147).  ERK has been shown to phosphorylate and increase the activity of the 
protein Elk-1, which induces c-fos expression (148, 149).  JNK has been reported to 
phosphorylate c-Jun for transcriptional activity (150).  p38 also increases c-fos expression 
mediated by Elk-1 (151).  C-fos and Jun dimerize into AP-1, which binds to the IL-2 
promoter to induce IL-2 production along with other transcription factors (e.g. NFAT, NFκB 
etc.) (152-157). 
It has been shown that the MAP kinase pathways regulate cellular proliferation.  
Several studies demonstrated that ERK1 and ERK2 are necessary for G1- to S- phase 
transition, induce positive regulators of the cell cycle (e.g. D-type cyclins, c-Myc) (158-161) 
and down-regulate genes inhibiting cell growth (Tob1, Ddit3, and JunD) (162).  However, it 
is still under debate whether proliferation and cell cycle progression in T cells rely on TCR 
signaling induced ERK1/2 activation or results from IL-2 production, leading to cell cycle 
entry or both (157, 163, 164).  P38 also has been shown to play a role in T cell proliferation, 
while JNK is not involved in T cell proliferation, but differentiation into Th1 (JNK2) or Th2 
(JNK1) subsets (165-168). 
MAP kinases are also involved in T cell survival.  Several studies revealed that 
ERK1/2 activation promoted cell survival by suppressing the pro-apoptotic machinery in the 
Jurkat T cell line (169-171).  It was also shown that ERK1/2 activation protects cells from 
glucocorticoid-induced apoptosis in T cells (172).  In contrast, it has been demonstrated that 
ERK pathway is involved in activation-induced cell death (AICD) of T cells (173, 174).  
JNK and p38 have also been shown to play a role in AICD in T cells (175, 176). 
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THE DIFFERENTIAL ROLE OF ERK1 AND ERK2  
? Of the key three MAP kinase pathways, ERK1 (MAPK3) and ERK2 (MAPK1) were 
the first mammalian MAPKs to be cloned, which are activated by mitogenic factors, 
differentiation stimuli and cytokines (122, 123, 177).  This pathway consists of Ras-Raf-
MEK-ERK.  GTP-bound form of Ras activates Raf-1 (MAPKKK).  Activated Raf-1, 
subsequently, phosphorylates MAP kinase kinase (MAPKK), MEK1 and MEK2 (178).  
MEK phosphorylates ERK1 and ERK2 on two critical residues, Tyr183 and Thr185.  
Activated ERK1 and ERK2 then translocate into the nucleus and activate several 
transcription factors.  The functional differences of ERK1 and ERK2, however, are not 
clearly demonstrated. 
 ERK1 and ERK2, which are 44kDa and 42 kDa in size, respectively, show 83% 
amino acid sequence homology and have been thought functionally redundant (140, 179, 
180).  Several lines of evidence in various species suggest that ERK1 and ERK2 have 
differential roles in development and differentiation (140, 181-187).  Knockout mice have 
used to study the distinct function of ERK1 and ERK2.  ERK1-/- mice are viable, fertile, and 
of normal size.  Additionally, Lefloch et al. demonstrated that there is no significant 
difference in cell proliferation, requirement of growth factor or cell cycle entry between 
ERK1-/- fibroblasts and wild-type cells (180).  On the other hand, disruption of the ERK2 
gene leads to early embryonic lethality (184, 185).  ERK2-/- mice die in utero at day E7.5 
due to impaired development of the trophoblast (185). 
In T cells, however, there has been very limited evidence for differential ERK1 and 
ERK2 expression leading to divergent signaling and function in T cells (138, 140, 188).  
Initially, Pages et al. demonstrated that in ERK1 knockout mice, thymocyte maturation was 
impaired and thymocyte proliferation following polyclonal stimulation was severely reduced 
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(140).  But subsequent studies in ERK1 knockout mice, demonstrated that ERK1-/- mice 
exhibit normal T cell effector function (e.g. cytokine production), but ERK1 -/- T cells show 
a slightly reduced proliferaion (189).  On the other hand, an earlier study using an ERK2 
conditional knockout approach to overcome embryonic lethality in ERK2 knockout mice, 
demonstrated that ERK2 is critical for checkpoints of thymocytes development especially in 
the DN3 and DN4 stages (188).  Recent studies also suggest that ERK2 is required for 
murine CD8+ T cell proliferation and survival, while ERK1 is dispensible for all aspects of 
CD8+T cell activation (179).  More recently, Wille, Kemp and other colleagues 
demonstrated with short hairpin RNA, that both ERK1 and ERK2 equivalently contribute to 
IL-2 production in human and mouse T cell lines (190, 191).  However, it has yet to be 
determined whether ERK1 and ERK2 play differential roles in primary human CD8+ T cell 
maturation subsets. 
 
SUMMARY OF PROBLEM AND HYPOTHESIS 
 While many studies have examined CD8+ memory T cell generation after either 
acute infection or persistent exposure to pathogens in mouse models, the precise 
mechanisms of CD8+ memory T cell generation and maintenance have not been completely 
understood in humans.  Since we still have to rely on cross-sectional assessment of memory 
T cell subsets by a multi-color flow cytometric approach, it is of significant importance to 
define the relationship between phenotype and function and the underlying molecular 
mechanisms that dictate the functional heterogeneity of maturation subsets.  
Moreover, few studies have focused on the role of late memory T cells, despite their 
known association with immunodeficiency states in humans.  The frequency of late stage 
memory T cells has been reported to increase with aging, possibly leading to increased risk 
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for infection in the elderly (192-194).  Our prior clinical studies have found that delayed 
immune reconstitution after cord blood transplantation is associated with skewing of the 
circulating T cell pool toward late memory cells, a likely result of a failure of thymopoiesis 
to renew the naïve and early memory T cell pool in this setting (195).   Hamann et al. and 
Champagne et al. have suggested that late memory T cells show impaired proliferative 
capacity.  In a murine model, Gattinoni et al. demonstrated that fully differentiated 
melanoma-specific effector cells had impaired antitumor efficacy, despite their ability to 
secrete abundant amounts of IFNγ and perforin and induce cytotoxicity, while earlier 
memory cells with identical specificity effectively controlled tumor growth (107).  These 
studies support the rationale that late memory CD8+ T cells may have a unique role, based 
on studies described above, suggesting that CD8+ late memory T cells are poorly 
associated with protective immunity.  We and others have demonstrated that late memory 
CD8+ T cells rarely produce IL-2.  Therefore, it is important to understand the molecular 
mechanism that determines the functional signatures of late memory CD8+ T cells. 
Initially, I demonstrated that human late memory CD8+ T cells have less ERK1/2 
phosphorylation following polyclonal stimulation with PMA: Ionomycin, leading to my 
hypothesis that down-regulation of the MAP kinase pathway including ERK1/2, contributes 
to lack of IL-2 production in human late memory CD8+ T cells.  Further studies also 
demonstrated that total ERK1, but not total ERK2, is down-regulated in human CD8+ late 
memory T cells.  Given these preliminary data and prior studies suggesting that the MAPK 
pathway is critical for IL-2 production in T cells, the hypothesis tested in this dissertation is 
that down-regulation of ERK1 leads to lack of IL-2 production in human late memory 
CD8+ T cells.  To test this hypothesis, I first investigated the functional signature of human 
naïve and memory CD8+ T cell subsets using multi-color cytokine flow cytometry.  
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Secondly, I determined the level of phospho-ERK1/2, and total ERK1 and ERK2 in 
activated and resting human naïve and memory CD8+ T cell subsets by multi-color 
molecular flow cytometry, western blotting and real-time RT PCR.  Finally, I determined 
whether ERK1 is sufficient or necessary for IL-2 production in human naïve and memory 
CD8+ T cell subsets by (a) a novel flow cytometry technique to measure cytokine 
production simultaneously with ERK1, and (b) manipulating ERK1 expression using over-
expression in late memory CD8+ T cells. 
Work in this dissertation has led to a understanding of the intrinsic functional 
signature of human CD8+ T cell maturation subsets.  This work enabled us to understand the 
molecular signature of human CD8+ T cell maturation subsets, dictating the functional 
signature.  This work also demonstrated the differential role of ERK1 and ERK2 isoforms in 
human CD8+ T cell maturation subsets, and confirmed that late memory CD8+ T cells have 
a unique functional and molecular signature.   
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CHAPTER 2 
MATERIALS AND METHODS 
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CELLS  
Peripheral blood mononuclear cells (PBMCs) were obtained by sedimentation using 
Histopaque 1077 (Sigma, St. Louis, MO) or Ficoll-Paque Plus (GE Healthcare, Piscataway, 
NJ) from CPD (Citrate-Phosphate-Dextrose) treated whole blood from healthy volunteers  
(obtained from Gulf Coast Regional Blood Bank, TX and from Continental Services Group, 
FL) (ranging in age from 32-60) and cryopreserved for further analysis.  All cell 
preparations were more than 95% viable by trypan blue exclusion.  For sorting CD8+ T cell 
maturation subsets, three methods for enriching CD8+ T cells (RosetteSep, EasySep (Stem 
Cell Technologies, Vancouver, BC, Canada), MACS CD8+ T cell isolation kit (Miltenyi 
Biotec, Auburn, CA)), were used during or after the sedimentation process. 
 
PREPARATION OF DENDRITIC CELLS 
Monocyte-derived dendritic cells (DCs) were generated in vitro from PBMCs by a 
previously described method (196).  Briefly, PBMCs were plated in a tissue culture flask in 
AIM V media supplemented with 10% human AB serum, penicillin, and streptomycin 
(Sigma, St Louis, MO) for 3 hours at which point non-adherent cells were discarded.  
Adherent cells were cultured with 500 IU/ml of recombinant interleukin 4 (rIL-4, R&D 
Systems, Minneapolis, MN) and 1000 IU/ml of granulocyte-macrophage colony stimulating 
factor (GM-CSF, Berlex Pharmaceuticals) and incubated at 37° C with 5% CO2.  After 5 
days, media was supplemented with 10 ng/ml of tumor necrosis factor alpha (TNF-α), 15 
ng/ml of IL-6, 10 ng/ml IL-1β, and 1 ug/ml of PGE2 (R&D Systems, Minneapolis, MN).  
After an additional 48 hours, mature dendritic cells were harvested and subsequently 
irradiated (25 Gy) before co-culture with responder PBMCs.  
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CYTOKINE FLOW CYTOMETRY (CFC) 
  106 thawed or fresh PBMCs were incubated with 10 µg/ml Staphylococcal 
enterotoxin B (SEB) (Sigma, St. Louis, MO), or 1 ng/ml phorbol 12-myristate 13-acetate 
(PMA) and 1 µM ionomycin together (Sigma, St. Louis, MO) in 96-well V-bottom plates in 
200 µl of media (RPMI1640; GIBCO Life Technologies, Grand Island, NY) supplemented 
with 10% FBS (Invitrogen, Carlsbad, CA).  For CMV-specific T cell stimulation, pools of 
pentadecapeptides spanning the CMV pp65 capsid antigen (Jerini Peptide Technologies, 
Berlin, Germany) were used to stimulate T cells in the presence of antibodies to CD28 and 
CD49d, as previously described (197, 198).  For inhibition, 1~10 µM U0126 or 1~10 nM 
tacrolimus were added.  After 1 hr, brefeldin A (Sigma, St. Louis, MO) was added to enable 
accumulation of intracellular cytokines.  Following an additional 5 hr incubation, cells were 
fixed and permeabilized with Fix & Perm A/B (Caltag, Burlingame, CA) and assessed the 
simultaneous expression of surface markers and intracellular effector proteins. 
 
ASSESSMENT OF NAÏVE AND MEMORY T CELLS SEGREGATION BY FLOW 
CYTOMETRY 
  FACS analyses were performed using monoclonal antibodies (mAbs) conjugated 
with the fluorochromes FITC, PerCP-Cy5.5, APC, PE-Cy7, PE, PE-Texas Red, APC-
Alexa750 or pacific blue and specific for human CD4, CD8, IL-2, TNFα, and MIP-1β (BD 
Pharmingen, San Jose, CA), CD45RA (Beckman Coulter, Fullerton, CA), CD27, IFNγ 
(eBiosciences, San Diego, CA) and CD57 mAb conjugated with biotin (BD Pharmingen, 
San Jose, CA) and furthermore Qdot705-streptavidin (Invitrogen, Camarillo, CA).  After 
staining, cells were washed, resuspended in PBS with 1% paraformaldehyde, and analyzed 
by 8-color 10-parameter  (or 9-color, for analyses including CD57) flow cytometry in a 
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Cyan cytometer (Dako, Carpinteria, CA) or an LSR-II cytometer (BD, San Jose, CA) using 
FlowJo software (Treestar, San Carlos, CA).  For most analyses, at least 3x105 total events 
(106 for CMV studies) were analyzed, with sequential gating of PBMC in a lymphocyte 
region (by scatter), on T cells (by assessing CD4+ or CD8+ and CD45RA+/CD27+ to 
demarcate naïve and memory cells staining for intracellular IL-2, IFNγ, TNFα, and MIP-
1β).  Gates defining cytokine-positive populations were defined based on the upper limits of 
fluorescence of unstimulated cells stained with the same antibodies.  The data were also 
confirmed by using dump channels (using monoclonal antibodies conjugated with FITC 
specific for CD14, CD19, CD16 and CD56) to exclude monocytes, B cells and NK cells, 
with equivalent results. 
 
MOLECULAR FLOW CYTOMETRY 
106 thawed or fresh PBMCs were incubated with 1 ng/ml PMA and 1 µM ionomycin 
together (Sigma, St. Louis, MO) in 96-well V-bottom plates in 200 µl of media (RPMI1640; 
GIBCO Life Technologies, Grand Island, NY) supplemented with 10% FBS (Invitrogen, 
Carlsbad, CA) for 5 min.  Following stimulation, cells were immediately fixed and 
permeabilized cells with Fix & Perm A/B (Caltag, Burlingame, CA) and assessed the 
simultaneous expression of surface markers and intracellular phospho-ERK1/2.  For total 
ERK1 and total ERK2 measurement, resting cells were fixed and permeabilized cells with 
Fix & Perm A/B. 
FACS analyses were performed using monoclonal antibodies (mAbs) conjugated 
with the fluorochromes FITC and specific for human CD4, CD14, CD19, CD56 (BD 
Pharmingen, San Jose, CA) (for the dump channel), and mAbs conjugated with the 
fluorochromes V450, PE, ECD and specific for human CD8, CD27 (BD Pharmingen, San 
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Jose, CA), and CD45RA (Beckman Coulter, Fullerton, CA).  Alternatively, analyses were 
performed using mAbs conjugated with the fluorochromes PE-Cy7, V450, APC H-7, FITC 
and specific for human CD4, CD8, CD27, CD57 (BD Pharmingen, San Jose, CA), and 
mAbs conjugated with the fluorochromes PE, ECD and specific for human CD28 or CMV 
pp65 A2 Tetramer (HLA-A2-restricted (NLVPMVATV, amino acids 495-503; hereafter 
referred to as A2-pp65) and CD45RA (Beckman Coulter, Fullerton, CA).  The expression of 
phospho-ERK1/2, total ERK1 and total ERK2 were assessed using rabbit anti-phospho-
ERK1/2 (1:50 in Caltag Fix/Perm buffer B) (Cell Signaling Technology), mouse anti-ERK1 
IgG2a (1:25 in Caltag Fix/Perm buffer B) (R&D Systems, Minneapolis, MN), and rabbit 
anti-ERK2 (1:25 in Caltag Fix/Perm buffer B) (Cell Signaling Technology, Danvers, MA), 
followed by secondary staining with donkey anti-rabbit IgG conjugated with Alexa 647 
(1:1,000 in Caltag Fix/Perm buffer B) (Molecular Probes, Eugene, OR) and donkey anti-
mouse IgG2a (1:500 in Caltag Fix/Perm buffer B) conjugated with APC (Jackson 
ImmunoResearch, West Grove, PA).  The same staining protocol was applied for PKCθ, 
Ras, C-Raf, MEK1, MEK2, Elk-1, JNK, p38, pan-calcineurin (rabbit IgG) (Cell Signaling 
Technology, Danvers, MA).  After staining, cells were washed, resuspended in PBS with 
1% paraformaldehyde, and analyzed by 5-color 7-parameter flow cytometry (or 7-color, for 
analyses including CD28, CD57) in a Cyan cytometer (Dako, Carpinteria, CA) or an LSR-II 
cytometer (BD, San Jose, CA) using FlowJo software (Treestar, San Carlos, CA).  
For the most analyses, at least 3x105 total events were analyzed, with sequential 
gating of PBMC in a lymphocyte region (by scatter), on T cells (by assessing CD8+ and 
CD45RA+/CD27+ to demarcate naïve and memory cells staining for intracellular phopho-
ERK1/2 and total ERK1 and ERK2).  Gates defining phospho-ERK1/2 positive populations 
and total ERK1 and ERK2 were defined based on the upper limits of fluorescence of 
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unstimulated cells stained with the same antibodies (phospho-ERK1/2), and of isotype 
controls (total ERK1 and ERK2).    
 
COMBINED FLOW CYTOMETRY  
 Following the same stimulation protocol as described in CFC (6 hours with PMA: 
Ionomycin or with 10 µg/mL CMV pp65 A2 restricted peptide (NLVPMVATV, amino 
acids 495-503), FACS analyses were performed using mAbs conjugated with the 
fluorochromes Alexa 700, FITC, PE-Cy7, V450, PE, APC-H7, PE-Texas Red, and specific 
for human CD4, CD8, IL-2, IFNγ, MIP-1β, CD27 (BD Pharmingen, San Jose, CA), 
CD45RA (Beckman Coulter, Fullerton, CA).  The expression of total ERK1 was assessed 
using mouse anti-ERK1 IgG2a (1:25 in Caltag Fix/Perm buffer B) (R&D Systems, 
Minneapolis, MN), followed by secondary staining with donkey anti-mouse IgG2a (1:500 in 
Caltag Fix/Perm buffer B) conjugated with APC (Jackson ImmunoResearch, West Grove, 
PA).  After staining, cells were washed, resuspended in PBS with 1% paraformaldehyde, 
and analyzed by 8-color 10-parameter flow cytometry in an LSR-II cytometer (BD, San 
Jose, CA) using FlowJo software (Treestar, San Carlos, CA).  For most analyses, at least 
3x105 total events were analyzed, with sequential gating of PBMC in a lymphocyte region 
(by scatter), on T cells (by assessing CD4+ and CD8+ and CD45RA+/CD27+ to demarcate 
naïve and memory cells staining for intracellular IL-2, IFNγ and MIP-1β and total ERK1).   
 
MULTIPLEX BEAD IMMUNOASSAY 
CD8+ T cell subsets sorted by FACS (over 99% purity), following staining using 
mAbs specific for CD45RA, CD27, and CD8 (excluding cells staining in a “dump” channel 
positive for CD4, CD14, CD16, CD19, and/or CD56) were stimulated with PMA and 
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Ionomycin for 6 hr.  Supernatants were stained using human chemokine 5-Plex reagents 
(Invitrogen, Camarillo, CA) following the manufacturer’s instructions and analyzed with a 
Luminex 100TM instrument (Luminex, Austin, TX). 
 
IN VITRO DIFFERENTIATION 
  Naïve cells were sorted on the basis of CD45RO negativity and expression of CD27 
by MACS microbeads (Miltenyi Biotec, Germany).  To induce T cell differentiation, 5µg 
Phytohemagglutinin (PHA) (Roche, Mannheim, Germany) and 100 IU/ml of recombinant 
human interleukin-2 (rh IL-2) (Sigma, St. Louis, MO) were added on d 1 and d 3 
respectively in RPMI media supplemented with 10% FBS.  Cells were split at 1:5 every 
three days and supplemented with rh IL-2. 
 
QUANTITATIVE REVERSE TRANSCRIPTION POLYMERASE CHAIN 
REACTION (qRT-PCR) 
CD8+ T cell subsets sorted by FACS (over 99% purity), following staining using 
mAbs specific for CD45RA, CD27, and CD8 (excluding cells staining in a “dump” channel 
positive for CD4, CD14, CD16, CD19, and/or CD56) were used for RNA extraction.  Total 
RNA was extracted from cells by using RNeasy Mini Kit (Qiagen, Valencia, CA) as 
followed by the manufacturer protocol.  RNA (100 ng) was reverse transcribed by using 
Oligo dT-primed cDNA reaction (Bio-Rad iScript Select cDNA synthesis kit).  The resulting 
cDNA was employed for qRT–PCR reactions.  These were performed in triplicate with 1 µl 
of cDNA from the reverse transcription mixture using Taqman Gene Expression Master Mix 
and Assays (corresponding to ERK1 (MAPK3), ERK2 (MAPK1) and GAPDH) (Applied 
Biosystems, NJ).  The total reaction mix was preincubated at 50°C for 2 min.  The protocol 
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for PCR consisted of denaturation at 95°C for 10 min, followed by 40 cycles of 15 seconds 
denaturation at 95°C and 1 minute of annealing and elongation at 60°C.  
 
IMMUNOBLOTTING 
Whole-cell lysates from CD8+ T cell subsets were prepared in lysis buffer 
(Radioimmunoprecipitation assay buffer, (RIPA)) (50mM Tris-HCl, 150mM NaCl, 0.5% 
Na.Deoxycholate, 0.1% SDS, 1% NP-40) (Thermo Scientific, Waltham, MA) supplemented 
with a protease inhibitor cocktail (Sigma, St. Louis, MO).  The lysates were centrifuged at 
13,000 rpm for 15 min at 4°C, and the supernatants were collected and quantified for protein 
concentration (by modified Bradford assay, Bio-Rad, Inc.).  A total of 25µg of protein was 
resolved on a 10% SDS-PAGE gel and then transferred to a PVDF membrane using a 
semidry transfer cell apparatus (Bio-Rad, Hercules, CA). The membranes were treated with 
5% nonfat milk for 1 hr to block nonspecific binding, rinsed, and incubated with mouse anti-
human ERK1 (1:2,000) (R&D system), rabbit anti-human ERK2 (1:2000) (Cell Signaling 
Technology) and mouse anti-human β-actin (1:3,000) (Sigma) overnight.  Signals were 
detected with HRP-conjugated anti-mouse IgG (1:3,000 for ERK1, 1:10,000 for β-actin) or 
anti-rabbit IgG (1:3,000) (Santa Cruz) using the ECL system (PerkinElmer, Waltham, MA). 
The same protocol was applied for whole-cell lysates from regulatory T cells 
(CD4+CD25highCD127low) or conventional CD4+ T cells, sorted by FACS, following 
staining using mAbs specific for CD4, CD25, and CD127 (excluding cells staining in a 
“dump” channel positive for CD8, CD14, CD16, CD19, and/or CD56). 
 
LENTIVIRAL TRANSDUCTION 
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 I sub-cloned human ERK1 cDNA into a Lenti-MP2 plasmid.   Briefy, tranfection of 
lentiviral plasmid, pMDL (gag/pol), pREV, and pVSVG (vesicular stomatitis virus 
glycoprotein) into 293T cells were done with jetPEI solution (Polyplus transfection, NY). 72 
hr after, viral particles were collected, cleared from cell debri by filtering and concentrated 
by spinning at 26,000 rpm for two hours.  Viral titer was measured by the concentration of 
p24. 
 For over-expressing ERK1 in human late memory CD8+ T cells sorted by FACS, 
30TU/cell of Lenti-MP2-ERK1 cDNA virus were transduced into 200,000 cells/100µL 
media in 96-well flat bottom plate, with ViraDuctin Lentivirus Transduction kit (Cell 
Biolabs, Inc., San Diego, CA) as well as 2,500rpm high-speed centrifugation for 1 hr.  5 
ng/ml IL-7, and IL-15 and 25 IU/ml IL-2 were added for maintaining cell viability (199).  At 
the 72 hr timepoint, cells were incubated with 1 ng/ml PMA and 1 µM ionomycin together 
in 96-well V-bottom plates in 200 µl of RPMI1640 supplemented with 10% FBS.  After 1 
hr, brefeldin A was added to enable accumulation of intracellular cytokines.  Following an 
additional 5 hr incubation, I fixed and permeabilized cells with Fix & Perm A/B (Caltag, 
Burlingame, CA) and assessed the simultaneous expression of surface markers and 
intracellular ERK1 and effector proteins (IL-2 and IFNγ).   
FACS analyses were performed using Aqua dye for dead cell exclusion (Molecular 
Probes, Eugene, OR) and mAbs conjugated with the fluorochromes, PE, V450, and specific 
for human IL-2, IFNγ (BD Pharmingen, San Jose, CA).  The expression of total ERK1 was 
assessed using mouse anti-ERK1 IgG2a (1:25 in Caltag Fix/Perm buffer B) (R&D Systems), 
followed by secondary staining with donkey anti-mouse IgG2a (1:500 in Caltag Fix/Perm 
buffer B) conjugated with APC (Jackson ImmunoResearch).  After staining, cells were 
washed, resuspended in PBS with 1% paraformaldehyde, and analyzed by flow cytometry in 
 33 
an LSR-II cytometer (BD, San Jose, CA) using FlowJo software (Treestar, San Carlos, CA).  
The production of IL-2 and IFNγ and the expression of ERK1 were assessed within live cell 
population (Aqua negative population) and compared with empty Lenti-MP2 virus-
transduced cells and mock-transduced (no virus) cells. 
 
ALLOGENEIC DENTRITIC CELL INDUCED T CELL PROLIFERATION 
To assess T cell proliferation in the presence or absence of U0126 (Cell Signaling 
Technology) or tacrolimus (FK506, Sigma), PBMCs were labeled them with 
2carboxyfluorescein diacetate (CFSE) (Molecular Probes, Eugene, OR), a highly fluorescent 
dye that is transferred to daughter cells, resulting in a linear decrease in fluorescence.  
Briefly, I labeled PBMCs with 2µM CFSE for 10 min at room temperature, quenched the 
reaction with FBS, and washed them twice with RPMI 1640 containing 10% FBS.  The 
frequency of proliferating CD4+ and CD8+ T cells was estimated after 7 d of mixed 
lymphocyte reaction (MLR) culture with allogeneic dendritic cells. 
 
STATISTICAL ANALYSES 
  Statistical analyses were performed using Prism software (GraphPad, San Diego, 
CA).  Intergroup comparisons were performed using Wilcoxon matched pair analysis and 
paired t-test.  All P values were two-tailed and considered significant if less than 0.05.  
Results were presented using Prism (GraphPad, San Diego, CA) and Illustrator (Adobe, 
Seattle, WA) using Macintosh computers (Apple, Cupertino, CA).  
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CHAPTER  3 
FUNCTIONAL SIGNATURE OF HUMAN CD8+ T CELL 
MATURATION SUBSETS: THE UNIQUE FUNCTION OF HUMAN 
LATE MEMORY CD8+ T CELL 
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 While most studies have focused on naïve and early stage memory CD8+ T cells, 
late memory CD8+ T cells have been less well studied with many assuming that late 
memory CD8+ T cells are simply exhausted cells.  Therefore, the extensive assessment of 
surface markers in combination with the production of effector cytokines in human CD8+ T 
cell maturation subsets will enhance our understanding of the role of late memory CD8+ T 
cells in protective immunity and determine whether they are identical to the exhausted T 
cells in mice or whether they have unique function besides cytotoxicity.  In this chapter, the 
functional signature of human CD8+ T cell maturation subsets by multi-color cytokine flow 
cytometry is presented to better define the unique function of human late memory CD8+ T 
cells. 
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RESULTS 
 
Higher order cytokine flow cytometry of human T cells.   
Cytokine flow cytometry was initially developed by Picker, et al. (200) to 
characterize both cell surface markers of human T cells and the production of effector 
cytokines at a single-cell level.  Following earlier methods published by de Rosa, et al. (201) 
and Roederer and colleagues (202) as well as other studies that have established the 
importance of polyfunctionality (previously defined by co-production of IL-2, IFNγ, TNFα, 
and MIP-1β (CCL4) (95, 96, 105, 109, 203)), I optimized an 8-color, 10-parameter flow 
cytometric approach that allowed us to simultaneously assess CD8+ lineage, maturation 
stages (defined by CD45RA and CD27) and the production of three cytokines (IL-2, IFNγ 
and TNFα) and one chemokine (MIP-1β).   
Analyses for subsequent studies were based on sequential gating of lymphocytes by 
forward/side scatter, CD8+ staining, and then on naïve and memory T cell subsets defined 
by the four quadrants demarcated by CD45RA and CD27 staining (Figure 4).  Although 
additional markers (e.g., CD62L, CCR7) may assist in the discrimination of naïve T cells, 
CD27 and CD45RA co-expression defines naïve human CD8+ T cells with up to 93% 
specificity, while the remaining three quadrants defined by these markers demarcate 
memory cells (201).  Individual studies have used inconsistent terms to describe memory 
subsets defined by CD27, CCR7 and CD45RA expression, including “central memory”, 
“effector memory” and “late memory” subsets.   However, it is widely accepted that the loss 
of CD27 expression is associated with maturation and that CD45RA re-expression 
characterizes late memory cells (61-63, 201, 204-206).  Thus, for the purpose of clarity I  
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Figure 4. Optimization of 8-color 10-parameter cytokine flow cytometry.  For the 
most analyses, at least 300,000 total events were acquired, with sequential gating of 
PBMC in a lymphocyte region by forward and side scatter, on CD8+ T cells and 
assessment of intracellular IL-2, IFNγ, TNFα, and MIP-1β within naïve and three CD8+ 
T cell maturation subsets demarcated by CD45RA and CD27 expression.   
 
Reproduced from Kim et al. J Immunol. 2009 Nov 15;183 (10):6167-74. Copyright 
2009. The American Association of Immunologists, Inc. 
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chose to classify cells as naïve (CD27+CD45RA+) or as progressively mature M1, M2 and 
M3 memory cells (M1: CD27+CD45RA–, M2: CD27–CD45RA, M3:  CD27–CD45RA+).   
Within CD8+ T cell subsets divided by maturation stage, I analyzed the simultaneous 
production of IL-2, IFNγ, TNFα and MIP-1β.  In most cases, for clarity, we displayed 
effector cytokine/chemokine production using 2-D plots (e.g., IL-2 vs. IFNγ staining or 
TNFα vs. MIP-1β staining) although all 15 possible combinations of one or more cytokines 
were always assessed. 
 
Maturation-dependent cytokine production signatures are independent of TCR 
stimulation.   
PBMCs were stimulated with PMA and ionomycin (P:I) to induce T cell activation.  
PMA and ionomycin directly activate protein kinase C-theta (PKCθ) while mobilizing 
intracellular calcium stores (207); this activation does not require TCR engagement or its 
most immediate downstream signaling events.   Consequently, P:I stimulation reflects the 
intrinsic ability of a cell to become activated irrespective of the expression of a given surface 
TCR and/or cell surface proteins (including CD27 and CD45RA) that might themselves 
modulate the activation threshold of a T cell.  I consistently observed a strong association 
between maturation stage and functional signature, as determined by cytokine production.  
The cytokine signatures by maturation stage induced by P:I stimulation in a representative 
subject are shown in Figure 5.  These results demonstrated significant polarization in naïve 
cells relative to M3 cells.  In contrast to the polarized production of individual cytokines 
noted in naïve and M3 cells, M1 and M2 cells produced heterogeneous combinations of 
cytokines (e.g. IL-2+IFNγ+ and TNFα+MIP-1β+ cells).  In addition, MIP-1β production 
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Figure 5. CD8+ T cell maturation is associated with stage-specific cytokine signature.  
The relationship between maturation stage and cytokine production pattern in PMA: 
Ionomycin-stimulated healthy donor PBMC was assessed as shown for a representative 
subject.  Two-dimensional contour plots depict IL-2 vs IFNγ staining and TNFα vs MIP-
1β staining within four CD8+ T cell maturation subsets; naïve (N: CD45RA+CD27+), 
early memory (M1: CD45RA-CD27+), intermediate memory (M2: CD45RA-CD27-), late 
memory (M3: CD45RA+CD27-).   
 
Reproduced from Kim et al. J Immunol. 2009 Nov 15;183 (10):6167-74. Copyright 2009. 
The American Association of Immunologists, Inc. 
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increases with progressive maturation of memory cells and is most prominent in M3 CD8+ 
T cells. 
 
Superantigen stimulation via the TCR induces characteristic cytokine signatures 
defined by maturation stage.   
Superantigens, including SEB, activate significant fractions of the T cell repertoire 
(~30%) (208, 209) by bridging MHC class II on APC and cognate TCR Vβ subsets unique 
to each superantigen (210).  Similar to the native activation of T cells by their cognate 
MHC-peptide ligands, superantigens activate the TCR signaling pathway through Lck-
ZAP70-PLCγ and other downstream intermediates (211, 212).  For this reason, SEB 
stimulation allows us to model the activation of antigen-specific T cells via the TCR, while 
affording the advantage of activating sufficient proportions of rare T cell subsets to yield 
informative results.  Based on this rationale, I stimulated peripheral PBMC derived from 
healthy subjects with SEB and examined the production of IL-2, IFNγ, TNFα and MIP-1β 
within naïve and memory (M1, M2 and M3) subsets.  While a lower proportion of CD8+ T 
cells are activated by SEB relative to P:I, I observed a similar polarization in cytokine 
signature from naïve to progressively mature memory CD8+ T cells (not shown).   
 
Late memory CD8+ T cells have a unique cytokine signature characterized by MIP-1β  
production without IL-2 
While this approach allowed me to individually analyze all 15 possible combinations 
of the four cytokines/chemokines, I first examined intracellular production of individual T 
cell effector proteins.  Aggregate results from ten subjects, consistent across the group, are 
shown in Figure 5.  For this analysis, the total production of each cytokine/chemokine was 
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summed, irrespective of whether production originated in a cell producing only one or 
multiple cytokines.  As shown in Figure 6, the bulk of IL-2 production in P:I-stimulated 
CD8+ T cells emanated from stimulated M1 cells.  While M2 cells did produce substantial 
amounts of IL-2, M3 cells produced little IL-2.  Similar results were seen with SEB 
stimulation (data not shown), suggesting that cytokine signature is an intrinsic property of 
cells at a given differentiation stage and independent of whether T cell activation occurs via 
the TCR (as for SEB) or by post-TCR activation (for P:I).  Production of IFNγ and TNFα 
was relatively consistent across M1, M2, and M3 subsets, and were increased significantly 
relative to the naïve subset (Figure 6, P<0.01).  In contrast, MIP-1β production 
progressively increased with maturation. 
 To better define how individual combinations contribute to the overall production of 
effector cytokines/chemokines within CD8+ T cell subsets, I assessed all of the 15 possible 
cytokine/chemokine combinations based on IL-2, IFNγ, TNFα and MIP1β production.  The 
production of each individual cytokine (or combination) was then represented as a 
percentage of the overall cytokine/chemokine production.  Data from ten healthy donors 
were analyzed in this fashion, and presented in the form of stacked bar graphs in Figure 7.  
These analyses allow me to clearly see which combination of cytokines/chemokines is 
predominant within the overall CD8+ population.  The overall composition of the CD8+ 
repertoire by maturation stage in these subjects is also shown (Fig. 2B, inset pie chart, mean 
± SD N: 33.5±12.4%, M1: 18.6±7.0%, M2: 24.6%±8.1% M3: 23.3±7.2%).  This analysis 
demonstrates that the dominant cytokine-producing combination is one characterized by 
MIP1β/TNFα/IFNγ co-production without IL-2; this functional subset primarily consists of 
M2 and M3 cells.  The next most common signatures consist of MIP1β/IFNγ co-producing 
cells (also mostly M2 and M3 cells) and the most polyfunctional (MIP1β/TNFα/IFNγ/IL-2) 
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Figure 6. CD8+ T cell maturation is associated with decreasing IL-2 and increasing 
MIP-1β  production.  Production of individual cytokines/chemokines by maturation stage. 
Total production of each cytokine/chemokine following PMA:Ionomycin (P:I) stimulation 
was summed, irrespective of whether such production originated in a cell producing only one 
or multiple cytokines, and then analyzed by production within N, M1, M2, and M3 stages 
within the CD8+ T cell population.  Results depict aggregate results from 10 healthy donors.  
** P<0.01, * P<0.05 
 
Reproduced from Kim et al. J Immunol. 2009 Nov 15;183 (10):6167-74. Copyright 2009. The 
American Association of Immunologists, Inc. 
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Figure 7. MIP-1β-producing polyfunctional cells are dominant within the CD8+ T 
cell population.  All 15 possible combinations of cytokines were analyzed with each 
combination assessed as a fraction of all cells producing one or more 
cytokines/chemokines in combination.  Each stacked bar reflects the overall proportion of 
cells producing a given combination of cytokines/chemokines; each bar is further divided 
by its production across the memory spectrum (white: N, light gray: M1, dark gray: M2, 
black: M3).  Results from 10 subjects were combined and presented in aggregate, with the 
inset pie graph revealing the distribution of naïve and memory cells across the population. 
 
Reproduced from Kim et al. J Immunol. 2009 Nov 15;183 (10):6167-74. Copyright 2009. 
The American Association of Immunologists, Inc. 
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subset.  Notably, all of the four most dominant signatures of cytokine/chemokine production 
include MIP1β production, while only one contains IL-2 producing cells. 
 
CD8+ CD57+ terminal memory T cells have further skewing to MIP-1β  production. 
I further determined whether CD57 within the M3 population could define distinct 
subsets of these cells.  Using a 9-color flow cytometric approach similar to that used above 
but also incorporating staining for CD57, I assessed an additional seven donors to determine 
whether CD57-positive and –negative M3 cells exhibited unique patterns of 
cytokine/chemokine production (Figure 8).  Consistent with our overall conclusion that 
memory maturation is associated with skewing in MIP1β:IL-2 production, I found relatively 
subtle, yet statistically significant, increases in MIP1β production and decreases in IL-2 
production in CD57-expressing M3 cells, consistent with their more differentiated 
phenotype.?
 
The CC-chemokines MIP-1α , MIP-1β , and RANTES are abundantly produced by late 
memory CD8+ T cells.   
To confirm that late memory maturation is characterized by increasing CC-
chemokine production and to determine whether the increasing MIP-1β production observed 
in late memory cells by cytokine flow cytometry reflects its actual secretion into 
supernatants, I performed a Multiplex Bead Immunoassay to measure the production of five 
chemokines (MIP-1α/CCL3, MIP-1β/CCL4, RANTES/CCL5, MCP-1/CCL2, and 
eotaxin/CCL11) simultaneously in supernatants produced by CD8+ T cell subsets (e.g. N, 
M1, M2, and M3) from five healthy donors, following stimulation with P:I for 6 hours.  
Consistent with the observation by intracellular staining that M3 CD8+ T cells produce 
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Figure 8. CD57+ M3 CD8+ T cells produce more MIP1-β  and less IL-2. A. The 
relationship between CD57 expression and cytokine production in M3 CD8+ T cells. We 
assessed the relationship between CD57 expression and functional signature in P:I-
stimulated healthy donor PBMC, as shown for a representative subject.  2-D dot plots depict 
IL-2 vs. IFNγ staining and TNFα vs. MIP-1β staining within CD57+/- M3 CD8+ T cell 
maturation subsets. B. The difference of production of individual cytokines/chemokines by 
CD57. Percentage of each cytokine/chemokine following P:I stimulation was calculated 
within CD57- M3 and CD57+ M3 stages in the CD8+ T cell population, irrespective of 
whether such production originated in a cell producing only one or multiple cytokines.  
Results depict aggregate results from 7 healthy donors. *P<0.05  
 
Reproduced from Kim et al. J Immunol. 2009 Nov 15;183 (10):6167-74. Copyright 2009. 
The American Association of Immunologists, Inc. 
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abundant MIP-1β (Figure 6), the concentration of secreted MIP-1β was highest in M3 
CD8+ T cells than other CD8+ T cell subsets (N, M1, M2, P<0.01) (Figure 9A).  
Furthermore, I also observed the per cell MIP-1β production, as assessed by measurement of 
the mean fluorescence intensity (MFI) of MIP-1β within chemokine-positive cells, was 
increased significantly in a stepwise fashion from the naïve to M3 phenotypic stages (Figure 
9B). I also found that the CCR5-binding CC-chemokines MIP-1α and RANTES were also 
primarily produced in M3 cells (P<0.05) (Figure 9A).  MCP-1 and eotaxin levels were too 
low to be determined (data not shown).  Taken together, late memory M3 CD8+ T cells are 
dominant producers of MIP-1β, MIP-1α, and RANTES, supporting our intracellular 
cytokine flow cytometry data and confirming that CC-chemokine production is strongly 
associated with late memory CD8+ T cell maturation. 
 
IL-2/IFNγ  co-producing cells rarely exist beyond the M2 stage.   
Recent studies have strongly suggested that the expression of individual effector 
cytokines (especially IFNγ) may be insufficient to identify human T cells most important for 
protective immunity to persistent viral pathogens (98, 108, 213-215).  Pantaleo, et al. (98) 
demonstrated that polyfunctional T cells, defined by IL-2 and IFNγ co-production, were 
critical for protective immune responses in studies of chronic and cleared infections.  Based 
on prior studies, I hypothesized that IL-2/IFNγ co-producing CD8+ T cells would be 
concentrated at certain stages of the maturation spectrum. 
Confirming this view, I found that the naïve and M3 CD8+ T cell compartments rarely 
contained cells capable of IL-2/IFNγ co-production, following either P:I or SEB stimulation 
(with results from ten subjects shown in Figure 10A).  For example, after P:I stimulation, 
the proportion of CD8+ T cells (mean±SD) with the IL-2+IFNγ+ phenotype by maturation
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Figure 9. Late memory (M3) CD8+ T cells are the predominant producer of CC 
chemokines. A. CD8+ T cells were FACS-sorted from PBMC from five healthy donors and 
stimulated with PMA: Ionomycin 6 hr and secreted chemokines (MIP-1β/MIP-
1α/RANTES) were measured using a multiplex bead immunoassay. (* P<0.05, ** P<0.01), 
B. Increasing MIP1β production per cell is a characteristic of memory maturation. We 
calculated the mean fluorescence intensity (MFI) of the MIP1-β+ population within CD8+ 
T cell maturation subsets (Naïve, N: CD27+CD45RA+, Early memory, M1: 
CD27+CD45RA-, Intermediate memory, M2: CD27-CD45RA-, Late memory, M3: CD27-
CD45RA+). Results depict aggregate results from 10 healthy donors. ** P<0.01  
 
Reproduced from Kim et al. J Immunol. 2009 Nov 15;183 (10):6167-74. Copyright 2009. 
The American Association of Immunologists, Inc. 
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Figure 10. IL-2/IFNγ  co-producing cells exist primarily at M1 and M2 stages.  A. IL-
2/IFNγ co-producing cells, known to be critical for protective immunity, were assessed for 
their production across the CD8+ T cell naïve/memory spectrum within 10 healthy 
donors.   The vast majority of these cells were present at the M1 and M2 stages (mean±SD 
for N: 8.4±3.7%, M1: 47.9±9.8%, M2: 37.7±11.7%, M3: 5.8±1.4% *P<0.01), B. Most IL-
2/IFNγ co-producing cells also produce IL-2 and/or MIP-1β.  We assessed the 
polyfunctionality of IL-2/IFNγ co-producing CD8+ T cells stimulated with P:I. (white: IL-
2+IFNγ+TNFα-MIP1β-, light gray: IL-2+IFNγ+MIP1β+TNFα-, dark gray: IL-
2+IFNγ+TNFα+MIP1β-, black: IL-2+IFNγ+TNFα+MIP1β+)  
 
Reproduced from Kim et al. J Immunol. 2009 Nov 15;183 (10):6167-74. Copyright 2009. 
The American Association of Immunologists, Inc. 
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stage was as follows: N, 7.2%±4.0%; M1, 53.0%±11.2%; M2, 35.8%±11.1%; M3, 
3.8%±2.3%.  Similar results were seen in CD8+ T cells following SEB stimulation (data not 
shown).  These results demonstrate that differentiation to an M3 CD8+ T cell is associated 
with the loss of the IL-2/IFNγ co-production.  Furthermore, I examined the production of 
TNFα and MIP-1β in IL-2/IFNγ co-producing cells and found that the vast majority of such 
cells also produced either TNFα and/or MIP-1β (Figure 10B).  Taken together, IL-2/IFNγ 
co-producing cells are confined to the M1 and M2 subsets, and rarely exist at the M3 subset.   
Moreover, these cells are functionally heterogeneous and usually produce other 
cytokines in addition to IL-2 and IFNγ.  These findings were also confirmed by an analysis 
of the maturation subsets producing each individual cytokine/chemokine or possible 
combinations.  In Table 1, the location within the CD8+ T cell maturation spectrum of the 
primary and secondary producer of each possible cytokine combination, in data derived 
from ten healthy subjects, is shown; the subset producing the greatest amount of each 
cytokine is highlighted in bold, while the standard typeface indicates the location of the 
second-most prolific producer. Cytokine signatures of CD8+ T cells stimulated by P:I (or 
SEB) are shown in Table 1.  It is evident from this analysis that the production of individual 
cytokines/chemokines (e.g., IL-2 without others) occurs primarily at the naïve or M1 stages; 
polyfunctional cells are increasingly produced at M1 and M2 stages, while progression to 
the M3 stage is again associated with monofunctionality, with prominent MIP-1β 
production.  This analysis also reaffirms that the subset defined by Pantaleo, et al. as 
polyfunctional on the basis of IL-2 and IFNγ co-production is actually quite heterogeneous, 
with IL-2/IFNγ co-producing cells rarely producing these two cytokines without additionally  
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N 
(CD27+CD45RA+) 
M1  
(CD27+CD45RA-) 
M2  
(CD27-CD45RA-) 
M3  
(CD27-CD45RA+) 
 
IL-2 
 
TNFα  
 
IFNγ/TNFα/MIP1β 
 
TNFα /MIP1β  
TNFα  IFNγ  IL-2/IFNγ/TNFα/MIP1β MIP1β  
IFNγ IL-2/TNFα  IL-2/IFNγ/TNFα IFNγ /TNFα  
 IL-2/ IFNγ /TNFα  IL-2/TNFα IFNγ /TNFα /MIP1β  
 IL-2/ IFNγ /TNFα /MIP1β    
 IL-2/IFNγ    
 IFNγ /TNFα    
Table 1. Dominant cytokine signatures by CD8+ T cell maturation stage.  For each 
possible cytokine/chemokine permutation the bold listing highlights the maturation 
stage that is the dominant producer of the given combination; when appropriate the 
standard typeface indicates the stage producing the second highest amount of the 
combination.   For example, cells producing IFNγ alone are found most commonly in 
the M1 compartment, followed by the N compartment.  
 
Reproduced from Kim et al. J Immunol. 2009 Nov 15;183 (10):6167-74. Copyright 
2009. The American Association of Immunologists, Inc. 
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producing TNFα and/or MIP-1β.  Finally, while M3 cells are the dominant source of MIP-
1β production, they rarely produce IL-2.   
 
Cytokine signatures of T cell maturation subsets can be induced by in vitro 
differentiation 
To formally demonstrate that maturation of peripheral T cells leads to alterations in 
functional cytokine production, I induced T cell differentiation from sorted naïve human T 
cells in vitro.  Previously, Brenchley et al. showed the relationship between cell division and 
functional or phenotypic changes following stimulation with PHA and SEB (216).  I 
previously demonstrated that prolonged stimulation of naïve CD45RA+CD62L+ human 
cord blood cells with PHA and IL-2 induced down-regulation of CD45RA and CD62L 
(217).  Based on these studies, I sorted naïve CD27+CD45RA+(CD45RO-) human 
peripheral T cells to at least 99% purity and stimulated them with P:I at baseline, and 
following seven and 14 days of culture in the presence of PHA and IL-2.   
I then analyzed the functional profiles of CD8+ T cells (Figure 11) within naïve, M1 
and M2 compartments.  Under these strong stimulation conditions, I was easily able to 
induce differentiation of naïve cells to the M1 subset, while fewer T cells were present at the 
M2 stage.  Similar to my prior experiments with peripheral CD8+ T cells, I found that naïve 
cells primarily produced IL-2; similarly, I saw the same transition toward polyfunctional T 
cells and toward MIP-1β-producing cells during differentiation through the M1 and M2 
stages.  These data provided direct confirmation that differentiation stage determines 
intrinsic functional status, as defined by cytokine production, in CD8+ T cells.
 52 
Figure 11. Cytokine signatures of CD8+ T cell maturation subsets can be induced by 
in vitro differentiation.  CD27+CD45RO- CD8+ naïve cells were exposed to PHA and 
IL-2 for 14 days in liquid culture.  Cells were harvested on day 0, 7 and 14 and re-
stimulated with P:I for 6 hours to assess cytokine/chemokine productions in CD8+ T cell 
maturation subsets by multi-color CFC as described above. (Day 0, TNFα: 0.7%, IFNγ: 
0.8%, MIP1β: 1.4% of total CD8+; Day 7, M1, TNFα: 22.9%, IFNγ: 7.9%, MIP1β: 
47.2% of CD8+M1, M2, TNFα: 16.8%, IFNγ: 24%, MIP1β: 26.7% of CD8+M2; Day 14, 
M1, TNFα: 36.7%, IFNγ: 10.4%, MIP1β: 38.5% of CD8+M1, M2, TNFα: 54.9%, IFNγ: 
51.2%, MIP1β: 67.0% of CD8+M2), (IL-2+IFNγ+, Day 0: 0.1% of CD8+, Day 7: M1, 
1.7% of CD8+M1, M2, 2.1% of CD8+M2, Day 14: M1, 1.4% of CD8+M1, M2, 7.7% of 
CD8+M2).  
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The cytokine production pattern of CD4+ T cell maturation subsets is similar to that of 
CD8+ T cell maturation subsets. 
Recently, the surface markers used to discriminate the CD8+ T cell maturation 
subsets (e.g. CD45RA, CCR7, CD27, CD28) have been adapted for CD4+ T cell lineage.  
Surprisingly, many phenotypic and functional similarities have been found between CD8+ 
and CD4+ T cell maturation subsets demarcated by same surface markers (68, 79, 80).  My 
data suggest that (a) as human CD4+ T cells progressively mature, MIP-1β production is 
increased, but IL-2 production is decreased, (b) IL-2/IFNγ co-producing cells are confined to 
the M1 and M2 subsets, and rarely exist at the M3 subset (Figure 12).  Consistent with 
others’ studies, my data also suggest that each CD4+ T cell maturation subset (N, M1, M2) 
has identical cytokine production pattern to corresponding CD8+ T cell subset (N, M1, M2).  
The percentage of late memory (M3) CD4+ T cell population is significantly low, so that it 
is impossible to consistently analyze the functional signature, although those small number 
of cells predominantly produce MIP-1β.  
 
The production of MIP-1β , and not IFNγ , by late-stage memory cells is the hallmark of 
the CMV-specific CD8+ T cell response.   
It has recently been suggested that mature CMV-specific CD4+ T cells acquire 
antiviral effector function and that their predominant combination of cytokine production is 
IFNγ/TNFα/MIP-1β (105).  I sought to more carefully examine the cytokine signature of 
CD8+ CMV-specific T cells, and the relationship of cytokine/chemokine production to 
maturation stage.  Therefore, I stimulated PBMC from eight healthy CMV-seropositive 
donors with a CMV pp65 peptide mixture (197, 198), and examined maturation and 
function.
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Figure 12. CD4+ T cell maturation is associated with decreasing IL-2 and increasing 
MIP-1β  production.  A. The relationship between maturation stage and cytokine 
production pattern in PMA: Ionomycin (P:I)-stimulated healthy donor PBMC was assessed 
as shown for a representative subject.  Two-dimensional contour plots depict IL-2 vs IFNγ 
staining and TNFα vs MIP-1β staining within four CD4+ T cell maturation subsets; naïve 
(N: CD45RA+CD27+), early memory (M1: CD45RA-CD27+), intermediate memory (M2: 
CD45RA-CD27-). B. Production of individual cytokines/chemokines by maturation stage. 
Total production of each cytokine/chemokine following P:I stimulation was summed, 
irrespective of whether such production originated in a cell producing only one or multiple 
cytokines, and then analyzed by production within N, M1, M2, and M3 stages within the 
CD8+ T cell population.  Results depict aggregate results from 10 healthy donors.  ** 
P<0.01, * P<0.05.  
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Consistent with prior observations suggesting the relative maturity of peripheral CMV-
specific T cells (67), I found that most functional CMV-specific T cells were in the M2 and 
M3 stages, as shown for a representative subject (Figure 13A).  I then analyzed the relative 
contribution of individual cytokines/chemokines (and combinations) to overall cytokine 
production in eight separate donors (Figure 13B).  The most striking finding was the most 
abundant functional subsets consisted of cells producing either MIP-1β alone (>60% of the 
total cytokine/chemokine response) or MIP-1β and other cytokines (especially 
IFNγ+TNFα+MIP-1β).  Consistent with my earlier observations that memory differentiation 
is associated with increasing production of MIP-1β, M2 and M3 cells were the primary 
source of this chemokine in CMV-specific CD8+ T cells.  Finally, I analyzed the production 
of IL-2/IFNγ co-producing cells.  These data (in Figure 13C) demonstrate that the 
distribution of these cells was consistent with that observed following SEB and P:I 
stimulation, reinforcing the notion that differentiation stage, rather than the nature of the 
activating stimulus, determines the functional signature.  Furthermore, these data suggest 
that skewing of the memory response to M3 results in functional T cells that produce 
abundant MIP-1β, but lack the ability to produce IL-2, a characteristic associated with 
pathogen clearance. 
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Figure 13.  Cytokine production signatures of CMV specific CD8+ T cells.  A. 
Functional assessment of CMV-specific CD8+ T cells across the maturation spectrum in a 
representative donor.  B. MIP-1β is the dominant cytokine/chemokine produced by CMV-
specific CD8+ T cells. Cytokine production profiles across the CD8+ T cell maturation 
spectrum in CMV pp65-stimulated PBMC from eight healthy CMV-seropositive donors. 
Inset pie charts depict the naïve/memory distribution of the functional CMV-specific 
CD8+T cell population (white: N, light gray: M1, dark gray: M2, black: M3) C. As for P:I-
stimulated cells, IL-2/IFNγ co-producing CD8+ T cells are primarily present within M1 and 
M2 stages (mean+SD, M1: 44.3±10.3% M2: 35.0±14.5% M3: 14.2±5.4% * P<0.01, 
negligible cytokine production in CMV-stimulated naïve cells excluded)  
 
Reproduced from Kim et al. J Immunol. 2009 Nov 15;183 (10):6167-74. Copyright 2009. 
The American Association of Immunologists, Inc. 
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CHAPTER  4 
THE DIFFERENTIAL EXPRESSION OF ERK1 AND ERK2, AND 
FUNCTIONAL CONSEQUENCE IN HUMAN CD8+ T CELL 
MATURATION SUBSETS  
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 Studies in Chapter 3 demonstrated functional differences in human CD8+ T cell 
maturation subsets with a cytokine signature that shifts from IL-2 production in early 
memory T cells to a pro-inflammatory chemokine production (CC-chemokine) in late 
memory T cells.  Late memory CD8+ T cells are characterized by the loss of IL-2 
production, an increase in MIP1- β production as well as an absence of co-production of IL-
2 and interferon-γ, along with the loss of proliferative capacity.  My preliminary data 
suggest that late memory CD8+ T cells have less ERK1/2 phosphorylation following 
polyclonal stimulation with PMA: Ionomycin.  Given these preliminary data and prior 
studies suggesting that the MAP kinase pathway is critical for IL-2 production in T cells 
(144-147, 152-157), I hypothesized that down-regulation of MAP kinase pathway including 
ERK1/2 in human CD8+ T cell maturation subsets alters their functional signature. 
 
Multi-color phospho/molecular flow cytometry 
 Flow cytometry has been a critical method of immunological research to characterize 
immune cells in terms of function, phenotype and other cellular events.  Recently, flow 
cytometry started being employed as a tool of molecular biology for cell cycle analysis, 
fluorescent protein detection or apoptosis measurement.  Furthermore, flow cytometry has 
been applied to single cell analyses of phosphorylation.  Initially, Rossi and other colleagues 
measured the phosphorylation events in peripheral blood using anti-phospho tyrosine 
antibody by flow cytometry (218).  Subsequently, overall phosphorylation status in CD4+ 
and CD8+ T cells following stimulation was measured, and employed for comparing HIV 
seropositive patients with non-infected individuals (219-221).  With the advance of 
generating phospho-specific antibodies against individual proteins, and of optimal 
permeabilization protocols (222), the measurement of phosphorylated molecules has been 
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performed in several studies (223-226).  These studies suggested that with an antibody 
specifically recognizing one phospho-epitope and optimal fixation/permeabilization 
methods, intracellular phospho proteins could be detected with flow cytomery. 
 Several studies using murine models, extended these technical advantages into 
measuring antigen-specific T cell responses.  Rosette et al. (227) and Zell et al. (223) 
respectively, showed the change of phosphorylation status in antigen-specific T cell 
response by flow cytometry.  In addition, Kaech et al. employed phopho-ERK1/2 as a read-
out to determine the differential signaling properties of lymphocytic choriomeningitis virus 
(LCMV)-specific CD8+ T cell memory subsets both in vitro and in vivo (121).  More efforts 
have been devoted to develop multi-color flow cytometric analysis for activation of multiple 
proteins along with surface markers in mice and human immune cells (228-232).  However, 
this approach requires careful optimization to consistently facilitate staining of multiple 
surface markers, reduce background, and to demonstrate consistency with other 
methodologies. 
Multi-color flow cytometry has several advantages as an approach to measure 
intracellular phospho-proteins (233).  The first advantage is the nature of objectively 
quantitative analysis, while immunohistochemistry relies on more subjective quantification 
or a semiquantitative manner of analysis.  Secondly, multi-color flow cytometry enables us 
to simultaneously measure multiple parameters (e.g. intracellular staining for effectors or 
molecules with surface markers or with apoptosis/proliferation/cell cycle indicators) at 
single cell level.  Most importantly, it is possible to assess the activation state of kinases in 
important signaling pathways within rare populations.  Currently, one of the major obstacles 
to studying signal transduction in rare populations such as human regulatory T cells or 
human late memory CD8+ T cells, is the lack of attaining suitable numbers of cells within 
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each subset to perform immunoblotting or standard kinase assays.   Immunoblotting also has 
a limited ability to define T cell heterogeneity, which can be more easily assessed using flow 
cytometry.  In this dissertation, I took advantage of multi-color flow cytomtry to detect 
phosph-ERK1/2 and total ERK1 and ERK2 along with four surface markers as well as two 
effector cytokines to define the relationship between the molecular and functional signatures 
of CD8+ T cell maturation subsets. 
 
RESULTS 
 
Optimization of multi-color phospho/molecular flow cytometry 
Given prior studies suggesting that the MAP kinase pathways, including ERK1/2 are 
critical for IL-2 production in T cells (144-147, 152-157) and my data (described in Chapter 
3) suggesting that late memory CD8+ T cells rarely produce IL-2, I sought to determine 
whether ERK1/2 phosphorylation is down-regulated in late memory CD8+ T cells.  I 
optimized a 5-color, 7-parameter flow cytometric approach that allowed me to 
simultaneously assess CD8+ lineage, maturation stages (defined by CD45RA and CD27) 
and the phosphorylation of ERK1/2, following polyclonal stimulation (Figure 14A) (PMA: 
Ionomycin (P:I), or anti-CD3 mAb).  Analyses for subsequent studies were based on 
sequential gating of lymphocytes by forward/side scatter, CD8+ gating following excluding 
unnecessary populations by dump channel (CD14, CD19, CD56, CD4), and then on naïve 
and memory T cell subsets demarcated by CD45RA and CD27 staining (naïve: 
CD27+CD45RA+, Early memory (M1): CD27+CD45RA–, Intermediate memory (M2): 
CD27–CD45RA, Late memory (M3):  CD27–CD45RA+).  Within CD8+ T cell subsets 
divided by maturation stage, I analyzed the phosphorylation of ERK1/2 (pERK1/2  
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Figure 14. Late memory CD8+ T cells have impaired ERK1/2 phosphorylation.  A. 
Optimization of 5-color 7-parameter phospho flow cytometry.  For the most analyses, at 
least 300,000 total events were acquired, with sequential gating of PBMC in a lymphocyte 
region by forward and side scatter, on CD8+ T cells (excluding unnecessary populations 
(CD4, CD14, CD19, CD56) and assessment of intracellular phospho-ERK1/2 within naïve 
and three CD8+ T cell maturation subsets demarcated by CD45RA and CD27 expression.  
B. Mean Fluorescence Intensity (MFI) of pERK1/2 following PMA:Ionomycin (P:I) 
stimulation was measured within the CD8+ T cell population.  Results depict aggregate 
results from 12 healthy donors.  ** P<0.01, * P<0.05 
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hereafter).  In most cases, I displayed histogram of pERK1/2 within CD8+ T cell 
subpopulations in PBMCs stimulated with P:I and anti-CD3 mAb (not shown), overlaid with 
one in corresponding unstimulated subpopulations (Figure 14A, not shown for anti-CD3 
mAb stimulation).  
 
ERK1/2 phosphorylation is diminished in human late memory CD8+ T cells. 
Initially, I assessed pERK1/2 (and phopho-CD3ζ) within CD8+ T cell subpopulations in 
PBMCs stimulated with anti-CD3 mAb.  I observed that the levels of pERK1/2 and phopho-
CD3ζ were decreased in CD8+ M2, and M3 T cells (Figure 21 in Chapter 5) 
In order to determine whether a lower level of pERK1/2 results from the activity of TCR 
proximal signaling molecules (e.g. CD3ζ, Zap-70) or from the activity or expression level of 
molecules distal to PKCθ (e.g. MEK1/2) or both, I stimulated PBMC with PMA and 
ionomycin (P:I) to induce T cell activation.  As mentioned in Chapter 3, P:I stimulation does 
not require TCR engagement or its most immediate downstream signaling events.   
Consequently, P:I stimulation reflects the signaling property of molecules downstream to 
PKCθ to become activated irrespective of the expression of a given surface TCR and/or 
intracellular molecules proximal to PKCθ.  I consistently observed a strong association 
between maturation stage and phosphorylation of ERK1/2, as determined by cytokine 
production.  Following 5 min P:I stimulation, ERK1/2 phosphorylation was displayed as 
bimodal distribution (lower peak was superimposed by unstimulated control) in M2 cells.  In 
M3 CD8+ T cells, ERK1/2 phosphorylation was almost superimposed with the unstimulated 
control, although there was a small shoulder of a positive peak (Figure 14A).  I, then, 
measured the mean fluorescence intensity (MFI) of pERK1/2 in CD8+ T cell maturation 
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subsets from 12 healthy donor PBMC (Figure 14B).  Interestingly, the MFI of pERK1/2 in 
M3 CD8+ T cells is significantly lower than that of N, M1 and M2 CD8+ T cells 
(P<0.0005), while the MFI of pERK1/2 in M1 CD8+ T cells is slightly lower than that naive 
CD8+ T cells (P<0.01).  These data suggest that in addition to down-regulated TCR- 
proximal signaling activity, the activity of signaling molecules downstream to PKCθ is 
diminished in M2 and M3 CD8+ T cells. 
 
ERK1 expression is diminished in human late memory CD8+ T cells 
To demonstrate whether lower phosphorylation of ERK1/2 in late memory CD8+ T 
cells results from down-regulation of total ERK1 or total ERK2 expression, I measured 
ERK1 and ERK2 protein expression respectively in FACS-sorted CD8 maturation subsets 
by immunoblotting.  I found that ERK1 expression is diminished by ~90% (by measuring 
densitometry) in M3 CD8+ T cells compared with M1 CD8+ T cells, while ERK2 
expression is equivalent among maturation subsets (Figure 15A).  I also demonstrated 
MEK1 expression was decreased, but not as much as ERK1 (Figure 22 in Chapter 5).  To 
further demonstrate whether ERK1 mRNA is also decreased in late memory CD8+ T cells, I 
performed quantitative RT-PCR with RNA extracted from FACS-sorted CD8+ T cell 
maturation subsets.  I showed that ERK1 mRNA level is also lower in M3 CD8+ T cells than 
in M1 CD8+ T cells (Figure 15B).  Since flow cytometry enables us to determine phenotype 
and function (e.g. cytokine production, cell proliferation, apoptosis) in a population 
containing very small number of cells, I optimized multi-color flow cytometry to measure 
total ERK1 and total ERK2 expression individually along with other surface markers.  Using 
this approach, I confirmed diminished total ERK1 expression in M3 CD8+ T cells compared 
with the M1 population by single cell level analysis (Figure 15C).  More interestingly, I  
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Figure 15. ERK1 expression is diminished in late memory CD8+ T cells.  A. ERK1 
and ERK2 protein expression in FACS-sorted CD8 maturation subsets respectively were 
assessed by immunoblotting.  By densitometry, ERK1 expression is diminished at ~90% 
in M3 CD8+ T cells (75% in M2) compared with M1 CD8+ T cells, while ERK2 
expression is equivalent among maturation subsets.  B. Quantitative RT-PCR with RNA 
extracted from FACS-sorted CD8+ T cell maturation subsets was performed to determine 
the mRNA level of ERK1 and ERK2. ERK1 and ERK2 mRNA level were normalized by 
the level of GAPDH.  Relative ratio of ERK1/GAPDH or ERK2/GAPDH of each subset 
to one of naïve CD8+ T cells was compared.  C. Multi-color molecular flow cytometry 
was used to assess ERK1 expression of CD8+ T cell maturation subsets in PBMC.  
Overlaid histograms indicate differential expression of ERK1 in CD8+ T cell maturation 
subsets. (Red: naïve (CD45RA+CD27+, N), Blue: early memory (CD45RA-CD27+, M1), 
Green: intermediate memory (CD45RA-CD27-, M2), Orange: late memory 
(CD45RA+CD27-, M3), Light blue: Isotype control) 
 
 
 
Multi-color molecular flow cytometry was used to assess ERK1 expression of CD8+ T 
cell maturation subsets in PBMC 
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found that M2 CD8+ T cells have bimodal expression of ERK1 (ERK1high and ERK1low). 
Taken together, ERK1 expression is decreased in M3 CD8+ T cells and a subpopulation of 
M2 CD8+ T cells, leading to a lower level of pERK1/2, while ERK2 expression is 
equivalent among CD8+ T cell maturation subsets. 
 
ERK1 expression is associated with IL-2 production in human CD8+ maturation 
subsets 
Based on prior studies suggesting that ERK1/2 is important for IL-2 production in T 
cells (144-147, 152-157), and my data suggesting that late memory (M3) CD8+ T cells 
rarely produce IL-2 and have down-regulated expression of ERK1, I hypothesized that 
down-regulation of ERK1 in human late memory CD8+ T cells leads to decreased 
production of IL-2.  To better demonstrate whether ERK1 expression is tightly associated 
with cytokine production in human CD8+ maturation subsets, I further optimized flow 
cytometry to simultaneously measure cytokine production (IL-2 and IFNγ) and ERK1 
expression in human CD8+ T cell subsets (CD45RA, CD27) in PBMC stimulated with P:I 
for 6 hours.  As shown in Figure 16A, most of IL-2 production emanated from the ERK1high 
population in CD8+ T cells (11.8% in ERK1high, vs 1.1% in ERK1low).  Accordingly, M3 
CD8+ T cells, which are mostly ERK1low, produced IL-2 at a significantly lower level, 
compared to M1 CD8+ T cells (Figure 16B).  As I showed in Chapter 3, the cytokine 
production pattern in M1 CD8+ T cells is heterogeneous, including IL-2+ and IL-2/IFNγ co-
production.  Therefore, M1 CD8+ T cells, which are a mostly ERK1high population, 
produced IL-2 in a higher level than any other populations.  Since I observed two 
subpopulations of M2 CD8+ T cells in terms of ERK1 expression, I further analyzed 
cytokine production pattern in ERK1high and ERK1low M2 subpopulations by sequential  
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Figure 16. IL-2 is produced by the ERK1high population of CD8+ T cells.  A. Multi-
color flow cytometry was optimized to simultaneously measure cytokine production (IL-2 
and IFNγ) and ERK1 expression in human CD8+ T cell subsets (CD45RA, CD27) in 
PBMC stimulated with P:I for 6 hours.  In total CD8+ T cells, IL-2 was mostly generated 
from ERK1high population.  B. By sequential gating, strong association between ERK1 and 
IL-2 was shown in each maturation subsets. C. Frequency of IL-2+, IL-2+IFNγ+ or IFNγ+ 
following PMA:Ionomycin (P:I) stimulation was measured within CD8+ T cell maturation 
subsets (M1, M2, and M3) and ERK1high and ERK1low subpopulation of M2.  Results depict 
aggregate results from 9 healthy donors.  ** P=0.0039, * P=0.0273 
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gating.  The ERK1low subpopulation of M2 CD8+ T cells has a similar cytokine production 
signature to M3 CD8+ T cells (e.g. relatively low IL-2 production), while the ERK1high 
subpopulation in the same subset produces abundant IL-2, similar to what I observed in M1 
CD8+ T cells.  Furthermore, my observations are very consistent among human healthy 
donors, suggesting ERK1 is a more critical marker to predict IL-2 production in human 
CD8+ T cell maturation subsets than any surface markers (Figure 16C).  Notably, the level 
of IFNγ production is identical regardless of CD8+ T cell maturation subsets and ERK1 
expression, as I found in Chapter 3.  These data suggest that ERK1 expression is strongly 
associated with IL-2 production in human CD8+ T cell maturation subsets. 
 
ERK1 expression is associated with CD28 expression 
It has been demonstrated that CD28-mediated signals potently enhance IL-2 
production, and IL-2R expression (234-237) and CD28 co-engagement induces ERK1/2 
phosphorylation only with engagement of the TCR-CD3 complex (238-240).  To determine 
whether the diminished expression of ERK1 and poor production of IL-2 in later stage 
CD8+ memory T cells (M3, and a subpopulation of M2), I assessed the expression of CD28 
with ERK1 expression in CD8+ T cell maturation subsets by multi-color flow cytometry.  I 
found that M3 CD8+ T cells expressed low levels of CD28, while CD28 expression in M1 
CD8+ T cells was uniformly high.  Interestingly, CD28 expression was substantially 
decreased in the ERK1low population of M2 (equivalent to M3), compared with the ERK1high 
M2 population (Figure 17).  In addition, to examine whether a terminal stage marker, CD57 
has any association with ERK1 expression in CD8+ T cell subsets, I further assessed CD57 
expression in association with ERK1 expression.  I found that CD57 expression was higher 
in the ERK1low population of M2 CD8+ T cells than in the ERK1high population.  Many M3  
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Figure 17. ERK1 expression is strongly associated with CD28 expression, and 
inversely correlated with CD57 expression.  Multi-color flow cytometry was optimized 
to simultaneously measure CD28, CD57 and ERK1 expression in human CD8+ T cell 
subsets (CD45RA, CD27) in PBMC.  In M2 CD8+ T cells, ERK1high subpopulation highly 
expresses CD28, but rarely expresses CD57.  ERK1low subpopulation of M2 CD8+ T cells 
does not express CD28, but does CD57.  Notably, most M1 cells express CD28, but not 
CD57, while M3 has opposite pattern of expression (CD28-, CD57high) 
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CD8+ T cells had high CD57 expression, while most of M1 CD8+ T cells expressed a low 
amount of CD57 (Figure 17).  Taken together, ERK1 expression is strongly associated with 
CD28 expression, and inversely correlated with CD57 expression. 
 
ERK1 expression is required for IL-2 production 
To determine whether ERK1 down-regulation is responsible for decreased 
production of IL-2, I delivered lentivirus-expressing human ERK1 cDNA into purified 
intermediate and late memory (M2, M3) CD8+ T cells.  Following P:I stimulation, I 
examined whether IL-2 production is increased in ERK1 over-expressed M2 and M3 CD8+ 
T cell populations.  M2 CD8+ T cells transduced with lentivirus expressing ERK1 cDNA, 
produced ~3 times more IL-2 than control virus transduced M2 CD8+ T cells (n=3) (Figure 
18A).  Additionally, M3 CD8+ T cells transduced with lentivirus expressing ERK1 cDNA, 
produced ~2.5 times more IL-2 than control M3 CD8+ T cells (n=3) (Figure 18B).   
Notably, I also found by using the Aqua, live-dead exclusion dye that ERK1 over-expression 
increased cell viability 2~4 times in M2 and M3 T cells (Figure 18A & B).  These data 
suggest that ERK1 expression is required for IL-2 production and cell survival in human 
CD8+ T cell maturation subsets. 
 
ERK1 expression can predict IL-2 production in CMV-specific CD8+ T cells. 
To demonstrate whether ERK1 expression dictates IL-2 production in antigen-
specific CD8+ T cell response, I measured ERK1 expression in CMV A2-tetramer+ CD8+ T 
cells (hereafter, CMV A2+ cells) along with surface markers.  As I expected from my prior 
data and others’ studies, CMV A2+ T cells were mostly in M2 and M3 CD8+ T cell subsets.  
I, then, assessed ERK1 expression in each subset and gated ERK1high and ERK1low 
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Figure 18. ERK1 restoration reconstitutes IL-2 production, and cell survival.  
Following transducing lentivirus expressing human ERK1 cDNA into purified intermediate 
(A) and late memory (B) CD8+ T cells, IL-2 production was measured by multi-color flow 
cytometry.  At the same time, cell viability was assessed by Aqua live-dead cell exclusion 
dye.  Experiments were done with cells from three healthy donors (n=3). 
 71 
subpopulations based on the separation of ERK1 expression in total CD8+ T cells (Figure 
19).  Compared with ERK1 expression in an M2 subset in total CD8+ T cells, CMV A2+ 
M2 T cells had relatively higher percentage of ERK1high population (19% vs 26%).  
Consistent with my prior observation suggesting that ERK1 expression is associated with 
IL-2 production, CMV A2+ ERK1high M2 cells produced higher level of IL-2 than CMV 
A2+ ERK1low M2 cells (1.1% vs 0.2%).  Of the responders (IL-2+ or IFNγ+), the percentage 
of IL-2 production was 23% in CMV A2+ ERK1high M2 cells, and 7% in CMV A2+ 
ERK1low M2 cells.  As expected, the ERK1 expression in M3 CMV A2+ cells was as low as 
that in M3 CD8+ T cells.  I, also, found that M3 CMV A2+ cells rarely produce IL-2 (0.1%, 
7% of total responder).  Although the total response of CMV A2+ M1 cells is relatively low 
(0.8%), the percentage of IL-2 production was 25% of the responders.  These data suggest 
that ERK1 expression predicts IL-2 production in CMV-specific T cells, and that CMV A2+ 
ERK1high M2 cells are similar to M1 cells and CMV A2+ ERK1low M2 cells are functionally 
similar to M3 cells. 
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Figure 19. ERK1 expression predicts IL-2 production in CMV-specific CD8+ T cells.  
Using multi-color flow cytometry, ERK1 expression was assessed in CMA A2-tetramer+ 
CD8+ T cells along with surface markers.  Separately, following stimulation with CMV 
A2 restricted peptide, IL-2/IFNγ production with ERK1 expression was determined in 
CD8+ T cell maturation subsets from the same CMV seropositive healthy donor. Overlaid 
histograms indicate differential expression of ERK1 in CMV A2+ CD8+ T cell maturation 
subsets (upper), and total CD8+ T cells (lower). (Red: early memory (CD45RA-CD27+, 
M1), Blue: intermediate memory (CD45RA-CD27-, M2), Green: late memory 
(CD45RA+CD27-, M3)).  In maturation subsets of CMV A2+ CD8+ T cells, ERK1 
expression was determined.  For comparison, ERK1 expression in corresponding CD8+ T 
cell maturation subsets was overlaid (Blue: CMV A2 tetramer+ CD8+ T cells, Red: total 
CD8+ T cells).   
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CHAPTER  5 
OTHER CHARACTERISTICS OF HUMAN LATE MEMORY CD8+ T 
CELLS 
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In Chapter 3, I described the functional uniqueness of human late memory (M3) 
CD8+ T cells.  In Chapter 4, I determined the differential expression of ERK1/2 in human 
CD8+ T cell maturation subsets to explain their functional heterogeneity and better 
understand the underlying mechanisms dictating the unique function of M3 CD8+ T cells.  
Although I proved that ERK1 expression is critical for IL-2 production in human CD8+ T 
cells and further showed that ERK1 down-regulation decreased IL-2 production in M3 
CD8+ T cells, it is evident that other signaling molecules and surface co-receptors can 
directly or indirectly control CD8+ T cell activation, and also IL-2 production.  Therefore, I 
sought to determine which TCR signaling molecules are key to the activation of human M3 
CD8+ T cells by molecular flow cytometry.  These findings, along with data showing the 
differential expression of α4β1 integrin in human T cell maturation subsets, leading to 
differential co-stimulatory effects of α4β1 integrin on each subset, are presented in this 
chapter. 
 
RESULTS 
 
Human late memory CD8+ T cells have impaired proximal TCR signaling cascades 
CD3ζ and ZAP70 are among the most proximal TCR signaling molecules, and are 
immediately phosphorylated by stimulation through the TCR/CD3 complex.  Therefore, it is 
important to determine the expression and phosphorylation of these two molecules in T cell 
maturation subsets to explain their functional heterogeneity, such as differential proliferation 
and cytokine production.  As I explained in Chapter 4, it has been difficult to study signal 
transduction in rare populations such as human Tregs or M3 CD8+ T cells, because of the 
difficulty obtaining suitable numbers of cells within each subset to perform immunoblotting 
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or kinase assays.  Again, I took advantage of multi-color flow cytomtry to examine whether 
there are differential proximal signaling events (e.g. via phospho-CD3ζ and phospho-
ZAP70) in CD8+ T cell maturation subsets. 
Following anti-CD3 mAb engagement for 5 min (with cross-linking with secondary 
antibody), I assessed phosphorylation of CD3ζ and ZAP70 within human CD8+ T cell 
maturation subsets present in purified bulk T cells.  I found that the phosphorylation of 
CD3ζ and ZAP70 was much lower in M2 and M3 CD8+ T cells than in Naïve and M1 
subsets (Figure 20).  I also observed similar findings in CD4+ T cells (lower in M2).  
Interestingly, there was no increase in phosphorylation of CD3ζ and ZAP70 in M3 CD8+ T 
cells regardless of anti-CD3 mAb dose, suggesting that the expression of total CD3ζ or 
ZAP70 is lower or the initiation of stimulation is impaired in M3 CD8+ T cells. 
To determine whether the initiation of stimulation is impaired in M3 CD8+ T cells, I 
assessed the expression of CD3ε, a cognate target for anti-CD3 mAb (clone: OKT3) in 
CD8+ T cell maturation subsets by multi-color flow cytometry.  To my surprise, the 
expression of CD3ε was substantially down-regulated in M3 population and partially in M2 
cells (Figure 21).  M2 cells in the CD4+ lineage also demonstrated down-regulation of 
CD3ε, but not to the same extent as M2 or M3 CD8+ T cells.  Given the observation from 
my preliminary studies, suggesting the expression of CD3ζ (not shown) is similar among 
CD8+ T cell maturation subsets, these data suggest that TCR-proximal signaling is impaired 
in late memory CD8+ T cells, due to down-regulation of CD3ε. 
 
JNK is down-regulated in late memory CD8+ T cells 
 While I demonstrated the functional consequence of ERK1 down-regulation in 
human late memory (M3) CD8+ T cells, I sought to determine whether other TCR signaling 
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Figure 20. T cell receptor proximal signaling is impaired in late memory CD8+ T cells.   
Using multi-color phospho flow cytometry, phospho-CD3ζ (A) and phospho-ZAP-70 (B) 
were assessed in CD4+ and CD8+ T cell maturation subsets following anti-CD3 mAb 
stimulation (Blue: stimulation with anti-CD3 mAb, Red: unstimulated).  It is noted that even 
10µg/ml anti-CD3 mAb rarely induce phosphorylation of CD3ζ and ZAP-70 in late 
memory (M3) CD8+ T cells, compared with other subsets. 
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Figure 21. The expression of CD3ε  is down-regulated in late memory CD8+ T cells.  
Using multi-color flow cytometry, CD3ε expression was assessed in CD4+ and CD8+ T cell 
maturation subsets.  CD56+ population (NK cells) (blue on far upper histogram) was used as 
a negative control for specific CD3ε staining.  CD56+ population was also removed to rule 
out possible contamination into M3 cells. Overlaid histograms indicate differential expression 
of CD3ε in CD8+ T cell maturation subsets. (Red: naïve (CD45RA+CD27+, N), Blue: early 
memory (CD45RA-CD27+, M1), Green: intermediate memory (CD45RA-CD27-, M2), 
Orange: late memory (CD45RA+CD27-, M3) 
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molecules are down-regulated in M3 cells, and if I can further explain the functional 
characteristics of M3 cells with other molecular changes.  So, I characterized the expression 
of other signaling molecules in CD8+ T cell maturation subsets by flow cytometry.  While I 
consistently observed ERK1 down-regulation in M3 population, I also found that MEK1 and 
JNK were similarly down-regulated in M3 cells (Figure 22).  However, by comparing the 
relative expression of each molecule in M3 cells to N, it was noted that the extent of down-
regulation of MEK1 and JNK was not nearly as much as that of ERK1 in M3 cells 
(ERK1MFI of N/ ERK1MFI of M3=5.5; JNKMFI of N/ JNKMFI of M3=1.9; MEK1MFI of N/ 
MEK1MFI of M3=1.5).  Interestingly, the expression of calcineurin in M3 cells was higher 
than in naïve CD8+ T cells, but equivalent to those of M1 and M2 CD8+ T cells (Figure 22, 
immunoblotting not shown).  These data suggest that alterations in other downstream TCR 
signaling in M3 CD8+ T cells, besides ERK1, may affect functional signature such as 
decreased production of IL-2 and prolific production of MIP-1β. 
 
VLA-4 (α4β1) integrin is highly expressed in late memory CD8+ T cells 
Several studies demonstrated that integrin α or β chain is highly expressed in 
effector T cells (51, 74, 201).  However, few studies demonstrated the expression of integrin 
by an antibody recognizing both the α and β chain (241).  To determine whether the 
augmentation of T cell activation by VLA-4 ligation differs in T cell maturation subsets, I 
evaluated the expression of VLA-4 using an antibody that recognizes both the α and β chain 
(241), while simultaneously measuring the phosphorylation of ERK1/2 and the production 
of IL-2 in maturation CD4+ T cell lineages, demarcated by CD45RA and CD27 staining.  
Although naïve CD4+ and CD8+ T cells expressed VLA-4, its costimulatory effect on 
phosphorylation of ERK1/2 and IL-2 production was not significant (Figure 23).  In 
 79 
Figure 22. TCR molecular signature of CD8+ T cell maturation subsets.  Multi-color 
molecular flow cytometry was used to assess ERK1 expression of CD8+ T cell maturation 
subsets in PBMC.  Overlaid histograms indicate differential expression of TCR signaling 
molecules in CD8+ T cell maturation subsets. (Orange: naïve (CD45RA+CD27+, N), Red: 
early memory (CD45RA-CD27+, M1), Green: intermediate memory (CD45RA-CD27-, 
M2), Blue: late memory (CD45RA+CD27-, M3)) 
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Figure 23. Co-engagement of α4β1 integrin augments Erk1/2 phosphorylation and 
the production of IL-2 in memory T cells.  A. Representative CD45RA/CD27 and α4β1 
integrin VLA-4 staining in CD4+ and CD8+ T cells. The expression of α4β1 integrin in 
memory CD4 T cell subsets (M1, M2, M3) is higher than naïve subset (isotype control: 
light blue, N: Red, M1: Blue, M2: Green, M3: Orange) (right). B. Representative Erk1/2 
phosphorylation (left) and IL-2/IFNγ production (right) in CD4+ T cell maturation subsets 
from a single subject, demonstrating augmented activation in memory CD4+ T cell 
subsets (M1, M2) following CD3/CD28/CD4 stimulation following co-engagement of 
VLA-4. For the most analyses, at least 300,000 total events were acquired, with sequential 
gating of PBMC in a lymphocyte region by scatter, on CD4+ T cells and assessment of 
intracellular p-Erk1/2 and IL-2 & IFNγ within three naïve and memory T cell maturation 
subsets demarcated by CD45RA and CD27 expression. 2-D dot plots reflect p-Erk1/2 on 
side scatter and IL-2 vs. IFNγ staining. C. Scatter plots demonstrating the synergistic 
effect of α4β1 integrin on intracellular Erk1/2 phosphorylation and IL-2/IFNγ production 
in CD4+ T cells from six healthy donors. Intergroup comparisons were performed using 
the Wilcoxon signed-rank test.  N.S.: not significant, * P<0.05. 
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contrast, M1, M2 and M3 T cells expressed higher levels of VLA-4 and demonstrated 
significantly augmented phophorylation of ERK1/2 and IL-2 production in both CD4 and 
CD8 lineages (Figure 23, data not shown for CD8+ T cell compartment).  These data 
suggest that VLA-4 binding augmented ERK1/2 phosphorylation and the IL-2 production in 
memory, but not in naïve subsets. 
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CHAPTER  6 
NOVEL APPROACH TO TREAT GRAFT-VERSUS-HOST DISEASE 
WITH RELATIVE SPARING OF CYTOMEGALOVIRUS (CMV)-
SPECIFIC IMMUNITY: SELECTIVE INHIBITION OF T CELL 
MATURATION SUBSETS 
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Allogeneic stem cell transplantation (SCT) has been widely used for patients with 
hematologic malignancies.  One of the limitations for successful allogeneic SCT is graft-
versus-host disease (GVHD) (242-245).  GVHD is an immune response mounted against the 
recipient of an allograft by mature donor T cells.  To reduce the risk of GVHD, most 
patients receive immunosuppressive medications after SCT or they receive manipulated 
allografts (e.g. depleted of T cells).  However, these strategies delay immune reconstitution, 
which increases the risk of infections, leading to the high mortality in allogeneic SCT 
setting.  Especially, current immunosuppressive drugs, such as steroids (246) and 
calcineurin inhibitors (247) are not selective enough to spare pathogen-specific T cells 
leading to an increased risk of life-threatening infections (e.g., CMV reactivation).  Current 
immunosuppressive drugs also abrogate T cell mediated graft-versus-tumor effects (GVT) 
(e.g. graft-versus-leukemia) (248).  Therefore, the development of novel approaches to 
promote the GVT effect of donor T cells and spare protective immunity against pathogens 
without inducing GVHD is critical for better therapeutic outcome of allogeneic SCT.   
Recent studies demonstrated the differential roles of T cell subsets on inducing 
GVHD.  Initially, Anderson, Shlomchik and colleagues demonstrated that memory CD4+ T 
cells induce neither clinical nor histological GVHD, while naïve CD4+ T cells do (249).  
Chen et al. also showed that adoptive transfer of allogeneic CD62L- memory T cells does 
not induce GVHD in a murine model (250).  Zheng et al. found that central memory T cells, 
but not effector memory T cells, induce GVDH (251, 252).  These studies suggest that naïve 
and central memory (or early memory) CD4+ and CD8+ T cells may be relatively more 
potent at inducing GVHD than effector memory (or intermediate) or late memory T cell 
subsets (249-254).   
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Another important T cell subset in GVHD is regulatory T cells (Tregs).  Preclinical 
transplantation murine models demonstrated that CD4+CD25+ Tregs reduce acute GVHD 
while sparing the GVT effect (255).  Additional studies suggest that higher donor graft 
CD4+ FoxP3+ T cell doses are associated with less acute GVHD in allogeneic peripheral 
blood SCT (256).  Currently, several groups are performing clinical trials on the adoptive 
transfer of ex vivo expanded Tregs to prevent GVHD (unpublished).  While the clinical 
utility of Tregs remains to be determined, Tregs are thought to be a critical player to 
suppress GVHD in allogeneic SCT.   
In addition, Appay et al. and I have shown that most CMV-specific T cells exist as 
relatively differentiated cells, and only a small number of these cells are found at early 
stages of the T cell maturation spectrum (66, 257).  Therefore, I reasoned that if there are 
signaling differences in T cell maturation subsets, they could be used to selectively inhibit 
naïve and early memory T cells, which have been reported to preferentially induce GVHD 
while sparing CMV-specific immune responses.  I found in Chapter 4, that naïve and early 
memory CD4+ and CD8+ T cells express two-fold higher expression of p-ERK1/2 than 
intermediate and late memory CD4+ and CD8+ T cells (p<0.0005) (Figure 24).  Given this 
rationale combined with my data on differential phosphorylation of ERK1/2 in human T cell 
maturation subsets, I hypothesized that the effects of MEK inhibition on T cell activation 
depend on levels of ERK1/2 phosphorylation.  To test this hypothesis, I measured cytokine 
production in activated T cell maturation subsets in the presence of MEK inhibitor (U0126) 
and the results are presented in this Chapter. 
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Figure 24. CD4+ and CD8+ T cell maturation subsets reveal differential 
phosphorylation of ERK1/2.  Optimization of 5-color 7-parameter phospho flow 
cytometry.  Using multi-color phospho flow cytometry, assessment of intracellular 
phospho-ERK1/2 was assessed within naïve and two CD4+ and three CD8+ T cell 
maturation subsets demarcated by CD45RA and CD27 expression, following 
PMA:Ionomycin (P:I) stimulation.  Mean Fluorescence Intensity (MFI) of pERK1/2 was 
measured within CD4+ and CD8+ T cell maturation subsets.  Results depict aggregate 
results from 12 healthy donors.  ** P<0.01, * P<0.05 
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RESULTS 
 
U0126 inhibits cytokine production in T cells in a stage-dependent manner 
I first determined the optimal dose of U0126 to suppress ERK1/2 phosphorylation.  
By both immunoblotting and phospho flow cytometry, I found that 1~10µM U0126 
efficiently suppressed ERK1/2 phosphorylation in human T cells in vitro (Figure 25).   
Next, I determined whether U0126 selectively suppresses cytokine production in a 
stage-dependent manner.  Using multi-color cytokine flow cytometry, I stimulated T cells in 
PBMC obtained from seven healthy donors by SEB in the presence of U0126 and measured 
IL-2, IFNγ and TNFα production in T cell maturation subsets.  In CD4+ T cells, both IL-2 
and TNFα production were significantly more suppressed in naïve and early memory subset 
(Mean reduction of IL-2 production, N: 79%, M1: 56%, M2: 50%, Mean reduction of 
TNFα, N: 87%, M1: 62%, M2: 48%).  In CD8+ cells, I observed similar pattern of reduction 
in IFNγ and TNFα production following MEK inhibition (Mean reduction of IFNγ 
production, N: 58%, M1: 30%, M2: 15%, M3: 0%, Mean reduction of TNFα, N: 70%, M1: 
55%, M2: 38%, M3: 5%) (P<0.05) (Figure 26).  Notably, a calcineurin inhibitor, 
tacrolimus, which is widely used in the clinical setting, suppressed the production of all 
three cytokines regardless of maturation stages at the dose equivalent to the usual 
therapeutic plasma concentration. 
 
U0126 suppresses allogeneic dendritic cell (allo-DC)-induced T cell proliferation with 
sparing of CMV-specific T cell function 
 To determine whether U0126 suppresses allo-DC-induced T cell activation in a 
degree equivalent to tacrolimus, I set up mixed lymphocyte reactions with mature DC from  
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Figure 25. MEK inhibitor, U0126 efficiently suppresses ERK1/2 phosphorylation in 
T cells. Using phospho flow cytometry (A), and immunoblotting (B), pERK1/2 was 
assessed in human T cells stimulated with P:I, in the presence of U0126.  For 
immunoblotting, total ERK1/2 and β-actin were measured for loading control. 
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Figure 26. Naïve and early memory T cells are preferentially inhibited by U0126. A. 
Using multi-color cytokine flow cytometry, I stimulated T cells in PBMC by SEB in the 
presence of 1µM U0126 and 1nM tacrolimus for 6 hours and measured IL-2, IFNγ and 
TNFα production in T cell maturation subsets.  B. The ratio of frequency of cytokine 
positive events treated with U0126 to frequency of cytokine positive events without U0126 
treatment (% of control) were measured within CD8+ T cell maturation subsets.  Results 
depict aggregate results from 7 healthy donors. * P<0.05 
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human monocytes in the presence of U0126 and tacrolimus.  U0126-treated CD4+ and 
CD8+ T cells were ~70% less activated than DMSO-treated cells, as assessed both by up-
regulation of the late activation marker, CD38 and by the CFSE proliferation assay.   
Tacrolimus-treated T cells were suppressed equivalently to U0126 (Figure 27).  Therefore, 
U0126 has the potency to suppress in vitro allo-DC-induced T cell proliferation at a similar 
efficiency to tacrolimus. 
In Chapter 3, I demonstrated that CMV-specific CD8+ T cells are mostly in M2 and 
M3 stages (Figure 13B).  Based on prior studies suggesting that most of allo-specific T cells 
are derived from the N and M1 (249-254) and my data suggesting MEK inhibition decreases 
cytokine production in SEB-stimulated T cells in a stage-dependent manner, I tested whether 
MEK inhibition spares cytokine production in CMV-specific T cells.  PBMC from a CMV 
seropositive donor were exposed to CMV pp65 peptide mix in the presence or absence of 
U0126 and tacrolimus.  6 hours after, TNFα production were assessed in T cell maturation 
subsets.  Tacrolimus substantially suppressed TNFα production irrespective of maturation 
stages (CD4+ M1: 85%, M2: 90%; CD8+ M1: 80%, M2: 70%, M3: 90%) of both CD4+ and 
CD8+ lineages.  However, U0126 did not suppress TNFα production in M2 and M3 stages 
as much as tacrolimus, although suppression was similar in the M1 stage (CD4+ M1: 87%, 
M2: 65%; CD8+ M1: 75%, M2: 15%, M3: 30%) (Figure 28). 
These data suggest that MEK inhibition results in potent suppression of allogeneic 
DC-induced T cell activation.  Moreover, MEK inhibition is maturation stage-dependent, 
and preferentially inhibits naïve and early memory cells thought to be critical for GVHD 
initiation, while relatively sparing late memory subsets, where CMV-specific immunity is 
concentrated.  
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Figure 27. U0126 suppresses T cell activation induced by allogeneic dendritic 
cells equivalently to tacrolimus.   For mixed lymphocyte reaction (MLR), CFSE-
labeled PBMCs were cultured with allogeneic mature dendritic cells in the presence of 
U0126 and tacrolimus for 7 days.  CFSE dilution and CD38 were measured by flow 
cytometry in CD4+ and CD8+ T cells by sequential gating.   
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Figure 28. U0126 selectively spares cytokine production in CMV-specific T cells 
compared with tacrolimus-treated T cells. Using multi-color cytokine flow 
cytometry, I stimulated T cells in PBMC from a CMV seropositive donor by CMV 
pp65 peptide mix in the presence of 1µM U0126 and 1nM tacrolimus for 6 hours and 
measured TNFα production in T cell maturation subsets.  The ratio of frequency of 
cytokine positive events treated with U0126 to frequency of cytokine positive events 
without U0126 treatment (% of control) were measured within CD8+ T cell 
maturation subsets.  Results depict aggregate results from a representative donor.  
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MEK inhibition does not suppress TGF-β  secretion in human regulatory T cells 
(Tregs) 
As explained above, Tregs are a critical player to suppress GVHD in allogeneic stem 
cell transplantation.  Recently, Zeiser et al. demonstrated that the function of Tregs is 
suppressed in vivo by the calcineurin inhibitor, Cyclosporine A (CsA) (258).  These data 
suggest that the inhibition of IL-2 production from other T cells by CsA suppresses Treg 
function.  In contrast, Kogina et al. showed that tacrolimus, another form of calcineurin-
inhibitor promoted proliferation of Tregs, while it did not induce cell conversion to Tregs 
(259).  These contradictory studies suggest that the effect of calcineurin inhibitors on Tregs 
in vitro and in vivo needs to be further investigated, since these drugs are widely used for 
reducing GVHD in the transplantation setting.  On the other hand, Luo et al. demonstrated 
that MEK inhibition induced FoxP3 expression in naïve CD4+CD25- T cells and MEK 
inhibitor-induced CD4+CD25+FoxP3+ T cells had suppressive function in vitro (260).  
More recently, Chen and other colleagues showed that blockade of IL-6 signaling augments 
Treg reconstitution in vivo and reduce GVHD (261). Taken together, these studies suggest 
that small molecular inhibitors and other types of blockade can manipulate the generation 
and function of Tregs to suppress GVHD, as an alternative therapeutic approach to ex vivo 
expansion and subsequent infusion of Tregs. 
It has been reported that TCR signaling is down-regulated in Tregs (262, 263).  For 
initial characterization, I examined the expression or phosphorylation of three key molecules 
in the TCR pathway, ERK1, ERK2 and pan-calcineurin in FACS-sorted Tregs defined by 
CD4+CD25highCD127low and in conventional CD4+ T cells (Tcons) by molecular flow 
cytometry and immunoblotting (Figure 29).  Consistent with prior data (262, 263), I found 
that following anti-CD3/28 or SEB stimulation, the level of ERK1/2 phosphorylation in  
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Figure 29. Regulatory T cells (Tregs) have distinct TCR signaling cascades.  A. 
Using multi-color phospho/molecular flow cytometry, phospho-ERK1/2, total ERK1, 
total ERK2 and Pan-calcineurin were assessed in Tregs and conventional CD4+ T 
cells (Tcons) in PBMC. A least 300,000 total events were acquired, with sequential 
gating of PBMC in a lymphocyte region by forward and side scatter, on CD4+ T cells 
(excluding unnecessary populations (CD8, CD14, CD19, CD56) and assessment of 
intracellular phospho-ERK1/2 within CD4+CD25highCD127low Tregs, and remaining 
Tcons following P:I stimulation.  Similarly, total ERK1, total ERK2 and pan-
calcineurin were assessed in Tregs and Tcons by overlaid histogram (Red: Tcon, Blue: 
Treg).  B. The expression of total ERK1/2 and pan-calcineurin were determined in 
FACS-sorted Tregs and Tcons by immunoblotting.  β-actin indicates loading control. 
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Tregs was lower than Tcons.  The expression of total ERK1/2 was also slightly, but not 
significantly, down-regulated, suggesting that upstream molecules of ERK1/2 from TCR can 
be impaired.  I also found that pan-calcineurin expression was lower in Tregs than in Tcons.  
These data suggest that two important arms in TCR signaling to activate T cells are impaired 
in Tregs. 
In order to determine whether MEK inhibition directly affect the function of Tregs, I 
measured membrane TGF-β (mTGF-β) in FACS-sorted Tregs, stimulated by anti-CD3/28 in 
the presence or absence of U0126 for 6 hours (264).  Interestingly, U0126 did not alter the 
expression of mTGF-β in activated Tregs (Figure 30).  Additionally, tacrolimus did not 
change the expression of mTGF-β in activated Tregs.  These data suggest that neither MEK 
inhibition nor calcineurin inhibition directly affect TGF-β secretion in Tregs. 
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Figure 30. MEK inhibition does not suppress TGF-β  secretion in human Tregs. 
Membrane TGF-β (mTGF-β) in FACS-sorted Tregs, was measured by flow cytometry 
following stimulation with anti-CD3/28 in the presence or absence of U0126 for 6 
hours.  Overlaid histogram was shown for comparison (Orange: resting Treg, Green: 
Treg stimulated with anti-CD3/28, Blue: Tcon stimulated with anti-CD3/28, Red: Treg 
stimulated with anti-CD3/28 in the presence of U0126 (A) or tacrolimus (B).  Tcons 
stimulated with anti-CD3/28 in the presence of U0126 or tacrolimus have similar 
intensity as Tcon stimulated with anti-CD3/28 (not shown) 
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CHAPTER  7 
DISCUSSION 
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The unique function of human late memory CD8+ T cells 
Recent technological advances, including development of improved instrumentation 
and reagents to facilitate “polychromatic” flow cytometry using monoclonal antibodies 
recognizing surface and intracellular proteins, have led to the recognition that there is 
dramatic phenotypic and functional heterogeneity of the peripheral T cell repertoire.  To 
better characterize the relationship between CD8+ T cell maturation stages and their 
cytokine signatures, we examined peripheral human CD8+ T cells in PBMC, stimulated 
with polyclonal activators and viral antigens, and systematically characterized the 
production of IL-2, IFNγ, TNFα and MIP-1β.  My results confirm the following: 1) Late 
memory (M3) CD8+ T cells produce little IL-2 (including IL-2/IFNγ co-production), but are 
prolific producers of MIP-1β, MIP-1α and RANTES; 2) MIP-1β is the most abundant 
cytokine produced by CMV-specific CD8+ T cells; 3) Nearly all IL-2 production occurs in 
N, M1, and M2 CD8+ T cells, while nearly all IL-2/IFNγ co-production occurs at the M1 
and M2 stage; and 4) Functional cytokine signature is strongly associated with T cell 
maturation stage in CD8+ T lineage and is largely independent of the type of stimulus 
initiating activation. 
Using both TCR-dependent stimulation (e.g., CMV antigens) and stimuli that bypass 
the TCR, requirements for co-stimulation and proximal signaling events (P:I), I found that 
maturation stage was closely tied to cytokine signature.  While I observed complexity in the 
various combinations of cytokines/chemokines produced by early and late memory CD8+ T 
cells, relatively simple rules could be used to model the effects of maturation on cytokine 
signature: 1) Early stage CD8+ T cells, including naïve cells, were more likely to be 
monofunctional with respect to cytokine/chemokine production, with IL-2 and TNFα 
production defining their cytokine signature; 2) Differentiation from naïve to the M1/M2 
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stages of CD8+ T cells is associated with increasing polyfunctionality, including co-
production of IL-2 and IFNγ, while progression to the M3 stage is again associated with 
monofunctionality; and 3) M3 CD8+ T cells are characterized by the production of abundant 
amounts of MIP-1β (often in concert with other cytokines) and other CC-chemokines (MIP-
1α and RANTES) and little, if any, IL-2.  These results are consistent with the results of 
Hamann et al. (51) and Sandberg et al. (87), who also found that CD27-CD8+ T cells rarely 
produce IL-2, although they produce perforin following polyclonal stimulation.  They also 
confirm the findings of Duvall et al., who demonstrated that subsets of HIV-2-specific 
CD8+ T cells making MIP-1β were more likely to express markers associated with more 
differentiated maturation states (97).   
My analysis of CMV-specific T cells confirmed the results of other studies 
demonstrating the abundance of later memory cells (i.e., M2 and M3 cells) within this 
antigen-specific population.  In contrast to my expectation that the most abundant product of 
CMV-specific T cells would be either IFNγ or TNFα, which have been most commonly 
utilized as functional markers of antigen-specific T cells (98, 105, 197, 198, 200, 265, 266), 
I found that MIP-1β was by far the most abundant cytokine produced by CD8+ CMV-
specific T cells stimulated ex vivo.  Besides cells producing MIP-1β alone, I found fairly 
robust numbers of cells producing MIP-1β in conjunction with effector cytokines, including 
IFNγ/TNFα/MIP-1β, IL-2/IFNγ/TNFα/MIP-1β, and IFNγ/MIP-1β were observed.  These 
data suggest that MIP-1β may actually be a more sensitive marker than IFNγ for the 
detection of CMV-specific T cells, and that conventional approaches (e.g., CFC or 
ELISPOT assays based on IFNγ detection alone) may significantly underestimate the 
frequency of CMV-specific T cells.  In addition, late memory (M3) CMV-specific T cells 
are also characterized by the lack of IL-2 production.   
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Taken together, my results establish an unequivocal link between maturation stage 
and functional cytokine/chemokine signature in CD8+ T cells, and demonstrate that late 
memory maturation results in polarization toward CC-chemokine production without IL-2 
production.  I also found that CMV-specific CD8+ T cells in healthy donors were heavily 
skewed toward late memory subsets, and that MIP-1β production dominates the functional 
signature of the human CMV-specific T cell response. Further studies in model systems and 
in the context of clinical trials, will be required to determine how the accumulation of late 
memory cells that are polarized toward CC-chemokine production influences outcomes in 
the setting of human disease states. 
 
The functional role of ERK1 in human CD8+ T cell maturation subsets 
I demonstrated that late memory CD8+ T cells are characterized by the loss of IL-2 
production, an increase in MIP1- β production and limited co-production of IL-2 and IFN-γ.  
Given prior studies suggesting that the MAP kinase pathway is critical for IL-2 production 
in T cells (144-147, 152-157), I tested the hypothesis that down-regulation of MAP kinase 
pathway including ERK1/2 in human CD8+ T cell maturation subsets contributes to their 
functional signature.   My results confirm the following: 1) ERK1/2 phosphorylation is 
lower in late memory (M3) CD8+ T cells than other subsets; 2) the expression of total 
ERK1, not ERK2, is down-regulated in M3 cells and in a subpopulation of M2 cells; 3) 
ERK1 expression is strongly associated with IL-2 production and CD28 expression in CD8+ 
T cell maturation subsets; and 4) ERK1 is required for IL-2 production in CD8+ T cell 
maturation subsets (Table 2). 
I further investigated the differential expression of TCR signaling molecules in 
CD8+ T cell maturation subsets.  Phospho/molecular flow cytometry enabled me to  
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Table 2. Summary of functional and molecular signatures of human late memory  
(M3) CD8+ T cells.  The uniqueness of M3 CD8+ T cells were described, compared 
with M1 (early memory) CD8+ T cells. 
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determine the expression of TCR signaling molecules even in M2 and M3 subsets, where the 
cell number is less than 15% of CD8+ T cells.  I found that TCR proximal signaling events 
(phospho-CD3ζ, phospho-ZAP-70) are down-regulated due to impaired expression of CD3ε 
in M3 cells (Figure 21 in Chapter 5).  This finding can explain the poor proliferation 
potential of M3 cells (204).  However, since the more distal signaling molecules, ultimately 
regulating transcription factors may more directly determine functions including cytokine 
production, I focused on the MAP kinase pathway distal to PKCθ.  PMA and ionomycin 
directly activate PKCθ while mobilizing intracellular calcium stores (207); this activation 
does not require TCR engagement or its most immediate downstream signaling events.  I 
consistently observed M2 and M3 cells express lower amounts of phosphorylated ERK1/2 
following P:I stimulation.  Additionally, this observation was reproduced in a time-course 
experiment, suggesting impaired ERK1/2 phosphorylation in M3 cells is due to lower 
activity of upstream molecules or lower expression of total ERK1/2.  In contrast to relatively 
equivalent expression of upstream molecules (PKCθ, Ras, c-Raf, MEK1/2) (Figure 22 in 
Chapter 5), ERK1 expression, but not ERK2, was much more down-regulated in M3 CD8+ 
T cells.  These data suggest that the differential phosphorylation of ERK1/2 depends on the 
level of ERK1 expression in CD8+ T cell maturation subsets.  More interestingly, I found 
that M2 CD8+ cells had a bimodal distribution of ERK1 (ERK1high and ERK1low), which 
would have been impossible to discover with traditional techniques such as immunoblotting. 
To better understand the relationship between the functional profile of M3 CD8+ T 
cells and the down-regulation of ERK1, I developed a multi-color flow cytometry approach 
to simultaneously detect ERK1, IL-2 and IFNγ along with surface markers of differentiation 
(CD8, CD45RA, C27, CD28 and CD57).  I found that 1) most IL-2 is produced by ERK1high 
CD8+ T cells; 2) CD28 expression is associated with ERK1 expression; 3) the cytokine 
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production pattern (high production of IL-2 and IL-2+IFNγ co-production) and higher CD28 
expression in the ERK1high subpopulation of M2 cells is close to M1 cells, whereas the 
features of the ERK1low subpopulation of M2 cells (poor production of IL-2 and lack of IL-
2+IFNγ co-production, no CD28 expression) is similar to M3 cells; and 4) ERK1 expression 
can predict IL-2 production in CMV-specific CD8+ T cells.  These data suggest that ERK1 
expression is strongly associated with IL-2 production and CD28 expression.  These data 
also suggest that ERK1 expression is a more accurate marker of functional memory CD8+ T 
cell maturation than the surface markers that are classically used to define maturation. 
 Knockout models have been utilized to determine the function of one gene in mice 
and zebrafish.  In humans, the manipulation of gene expression has been performed by 
delivering dominant-negative constructs or gene-expression vectors into cell lines in vitro to 
elucidate the relationship between gene expression and its functional consequence.  The 
recent advancement of delivery systems of gene-expression vector using lentivirus enabled 
us to examine the function of ERK1 in primary human CD8+ T cells.  I showed that over-
expression of ERK1 increased IL-2 production in M2 and M3 cells.  These data suggest that 
IL-2 production is dependent on ERK1 expression in human CD8+ T cell maturation 
subsets. 
I also determined the association between ERK1 and IL-2 production in CMV pp65 
A2+ T cells.  Along with tetramer staining, I found that CMV A2+ ERK1high M2 cells 
produced higher levels of IL-2 than CMV A2+ ERK1low M2 cells.  These observations are 
consistent with my prior observation suggesting that ERK1 expression is associated with IL-
2 production in human CD8+ T cells.  As expected, M3 CMV A2+ cells rarely produce IL-
2.  However, it remains to be elucidated why ERK1 expression in CMV A2+ cells is skewed 
into the center rather than the bimodal distribution in overall CD8+ compartment, leading to 
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relatively ambiguous separation of ERK1high and ERK1low subpopulations, and why the 
response of CMV A2+ M1 cells is low.  
 In conclusion, I demonstrated a strong association between ERK1 expression and IL-
2 production in human CD8+ T cells.  I also demonstrated that the functional consequence 
of ERK1 down-regulation in human late memory CD8+ T cells is poor production of IL-2.  
My studies are one of the first demonstrations that genetic modulation may skew the 
functional signature of primary human CD8+ T cells.  In addition, my studies demonstrated 
loss of ERK1 expression may explain prior studies demonstrating why late memory CD8+ T 
cells are functionally impaired with a poor ability to produce IL-2, to respond 
polyfunctionally and to proliferate in response to stimulation.   
 
MEK inhibition decreases cytokine production in human T cells in a stage-dependent 
manner 
Recent studies suggest that most allo-reactive T cells, which induce GVHD, exist in 
naïve and early memory stages (249-254), while most CMV-specific T cells are in 
intermediate and late memory stages (66, 257).  Therefore, it would be ideal to selectively 
inhibit naïve and early memory T cells, and spare later stage memory T cells following 
allogeneic stem cell transplantation (SCT).  In other words, GVHD could be reduced 
without impairing immunity to CMV reactivation.  Therefore, I sought to determine 
signaling difference between T cell maturation subsets that could be explored to develop 
more rational immunosuppressive strategies.  Given this rationale and my data about 
differential phosphorylation of ERK1/2 in human T cell maturation subsets (pERK1/2 in N 
& M1 is greater than pERK1/2 in M2 or M3), I tested the hypothesis that the effects of MEK 
inhibition on T cell activation depend on levels of ERK1/2 phosphorylation.  I found that: 1) 
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MEK inhibitor (U0126) suppresses cytokine production in T cells in a stage-dependent 
manner, while a calcineurin inhibitor, tacrolimus at a therapeutic plasma concentration 
suppressed the production of all three cytokines regardless of maturation stage; 2) MEK 
inhibitor (U0126) suppresses allogeneic dendritic cell (DC)-induced T cell proliferation 
while relatively sparing CMV-specific T cell responses; and 3) MEK inhibition does not 
suppress TGF-β secretion in human Tregs.   
 Very recently, ERK1/2 have been reported to be phosphorylated in T cells in a 
mouse GVHD model and that MEK inhibition reduces GVHD (267).  My results showed 
that the expression of calcineurin in memory CD4+ and CD8+ T cells (not shown for CD4+ 
T cells, Figure 22 in Chapter 5 for CD8+ T cells) was higher than in the naïve population.  
If the expression levels of calcineurin reflect the functional significance of the pathway, one 
could expect that a calcineurin inhibitor, tacrolimus would suppress memory subsets 
preferentially.  In fact, I found that tacrolimus suppressed SEB- induced cytokine production 
non-selectively in T cell maturation subsets.  In contrast to tacrolimus, U0126 suppressed 
cytokine production preferentially in naïve and early memory stages of T cells.  These data 
suggest that the phosphorylation level of ERK1/2 more accurately reflects the functional 
significance of the pathway at each maturation stage of T cells, and that MEK inhibition 
induces T cell memory stage-specific immunosuppression following polyclonal stimulation. 
 To mimic GVHD initiation with an experimental model, I performed an MLR with 
mature allogeneic DC and measured CMV-specific T cell responses in the presence of 
U0126 or tacrolimus.  I demonstrated that U0126 suppressed potent allo-DC induced T cell 
proliferation equivalently to tacrolimus, but spared CMV-specific T cell responses.  
Tacrolimus, however, suppressed CMV-specific T cell responses in all memory T cell 
stages.  These data suggest that the MEK inhibitor suppressed activation of allo-reactive T 
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cells, which are mostly in naïve and M1, but did not suppress activation of CMV-specific T 
cells, which are mostly in M2 and M3.  
Tregs also play a role in reducing GVHD, and are potentially targets of 
immunosuppression, which may undermine the potential benefit MEK inhibition could 
provide in sparing CMV immunity.  Therefore, to determine whether MEK inhibition 
suppresses Treg function, I measured mTGFβ in Tregs stimulated with anti-CD3/28 in the 
presence or absence of U0126.  I found that U0126 did not suppress the expression of 
mTGFβ in Tregs, suggesting that the MAP kinase pathway is not important in releasing 
TGFβ.  However, it has to be determined whether the MAP kinase pathway is important in 
the synthesis of TGFβ.  Interestingly, tacrolimus also did not suppress the expression of 
mTGFβ in Tregs.  Recent studies suggest that cyclosporine A (CsA) suppresses Treg 
function, because IL-2 production from other T cells, which is also important for the 
function of Treg, was suppressed by CsA (258).  In contrast, other studies suggested that 
U0126 increased FoxP3 expression, the number of inducible Tregs, and their suppressive 
function (260).  Taken together, neither MEK inhibitors nor calcineurin inhibitors directly 
affect the expression of mTGFβ, but others’ data suggest that MEK inhibitors could 
positively affect the Treg number or function, while calcineurin inhibitors may negatively 
affect them. 
In conclusion, MEK inhibition suppresses T cell activation in a stage-dependent 
manner, leading to selective immunosuppression of allo-reactive T cells with sparing of the 
CMV-specific T cell response and the function of Tregs.  These experimental models also 
suggest that MEK inhibition might have therapeutic potential to treat GVHD instead of or in 
addition to calcineurin inhibitors, although further studies in murine models and humans are 
necessary. 
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FUTURE PERSPECTIVES 
Collectively, this dissertation demonstrates the functional heterogeneity of human 
CD8+ T cell maturation subsets and the role of ERK1 on CD8+ T cell maturation subsets.   
More specifically, this dissertation shows that ERK1 is down-regulated in human late 
memory CD8+ T cells, leading to poor production of IL-2.   
However, there remain potential problems and several important questions regarding 
the functional signature of late memory CD8+ T cells.  A major limitation of my study was 
the use of only two markers to define naïve and memory subsets.  I acknowledge that the use 
of additional markers to define naïve and memory subsets, while adding complexity to my 
experimental approach, would likely have defined both naïve and memory subsets with 
greater specificity.  For example, de Rosa et al. (201) found that the addition of a third 
memory/naïve marker increased the specificity of definition of naïve CD8+ T cells from up 
to 87-93% to approximately 96%.  A second limitation of this work is that I only studied 
antigen-specific immunity to only one virus.  My studies of CMV-specific CD8+ T cells 
should be cautiously interpreted with respect to their relevance to T cell responses to other 
pathogens.  It is very likely that individual viruses differ in their susceptibility to individual 
mechanisms of CD8+ T cell control; the caveat that “individual results may vary” should be 
considered when considering the unique functional profiles that constitute protective 
immune responses to specific pathogens.  Third, the balance between the functions of M3 
cells (e.g. chemotaxis) and those of earlier memory cells that appear to be more important 
for viral clearance (e.g., polyfunctional M1, M2 cells) deserves further investigation.  It will 
also be important to elucidate the mechanisms that govern maturation and migration through 
activated functional stages and to determine how the production of CC-chemokines is 
associated with CCR5 expression on T cells and myeloid subpopulations in vivo.   
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Additional questions regarding the molecular signature of late memory (M3) CD8+ 
T cells to dictate their function also need to be answered.  First, I acknowledge that there 
must be additional genetic changes that contribute to the function of CD8+ T cell maturation 
subsets.  I already demonstrated that JNK was also down-regulated in M3 cells, suggesting 
that the down-regulation of JNK can contribute to poor production of IL-2 in M3 CD8+ T 
cells and that JNK-Jun pathway can be also important for maximal IL-2 production in 
human CD8+ T cells.  Recent studies in mouse models suggest that ERK2 is critical for 
CD8+ T cell proliferation and survival (179).  The function of ERK2 also needs to be 
investigated in human CD8+ T cell maturation subsets.  Secondly, it will be critical to better 
define the role of epigenetic changes associated with phenotypic and functional 
differentiation.  It has been shown that CpG methylation of cytokine promoter regions 
modify functional cytokine profiles of both CD4 and CD8 memory T cells (268, 269).  I 
observed that naïve CD8+ T cells do not produce as much IL-2 as M1 cells, although those 
cells have considerable expression of ERK1.  These data raise a possibility that the IL-2 
promoter could be hyper-methylated in the naïve population compared to M1 cells.  
Additionally, the mechanism of ERK1 down-regulation could be direct or indirect 
epigenetic changes, via methylation or microRNA expression.  Finally, it is important to 
investigate what other pathways are involved in cytokine and chemokine secretion in M3 
CD8+ T cells.  Recently, Krishnan et al. demonstrated that FcRγ and Syk kinase replace 
CD3ζ-chain and ZAP-70 in human effector CD4+ T cells (270).  These studies suggest that 
there could be other pathways, possibly FcRγ and Syk kinase to induce cytokine and 
chemokine secretion in M3 CD8+ T cells.   
Chapter 6 in this dissertation demonstrates that MEK inhibition suppresses cytokine 
production in T cells in a maturation stage-dependent manner.  It was based on the 
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hypothesis that the differential activation and expression of ERK1/2 reflect their unique 
utility in T cell subsets.  These data suggest a novel potential therapeutic approach to reduce 
GVHD while sparing protective immunity against CMV and other critical pathogens in the 
allogeneic SCT setting.  Several questions regarding subset or stage-specific immuno-
suppression also need to be answered.  First, I acknowledge that MEK1-ERK1/2 pathway is 
not an ideal target for selective inhibition because ERK1/2 expression shows a spectrum 
through naïve and later stage memory T cells.  Accordingly, I observed that cytokine 
suppression by MEK inhibitor was revealed as a spectrum, not as ‘all or none’.   Therefore, 
it is important to find other targets, which are more exclusively expressed or activated at 
certain stages of T cell maturation by novel high throughput methods, such as by reverse 
phase protein array.  Our results suggest a proof of concept that stage-specific inhibition is 
achievable.  Secondly, it needs to be determined whether MEK inhibitor reduces T cell 
survival in a stage-dependent manner.  Finally, the effect of MEK inhibitor on reducing 
GVHD with sparing of virus-specific T cell responses needs to be confirmed in murine 
models to understand if this strategy might be translated in vivo for therapeutic benefit. 
 
BIOLOGICAL/CLINICAL SIGNIFICANCE AND CONCLUSIONS 
This dissertation highlighted the functional significance of human late memory 
CD8+ T cells.  It provided new insight to understand the role of late memory CD8+ T cells 
in the physiologic (desired) (e.g. chemotaxis besides cytotoxicity) and pathologic 
(undesired) immunological processes (e.g. GVHD) in the human body.  More importantly, 
results from these studies will provide a better understanding of the relationship between 
maturation stage and functional heterogeneity and facilitate better immune monitoring 
strategies and immune modulation.  
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Our group’s prior studies of late memory CMV-specific T cells (e.g., those 
expressing CD57, which defines cells that would most likely have been defined as M3 in 
this study) suggests that greater frequencies of cells residing within this population are 
associated with poor control of CMV reactivation after stem cell transplantation, supporting 
the view that polyfunctional cells producing IL-2 may be better at controlling pathogenic 
viral infections.  Studies by Restifo and colleagues (107) in a cancer immunotherapy model 
also suggest that late effector T cells, characterized by strong cytotoxic function and IFNγ 
production, may be paradoxically inferior in their ability to control cancer growth.   While 
higher-order cytometric analyses were not reported, this report showed that late effector 
cells, while producing IFNγ and having greater cytolytic capacity, were deficient in IL-2 
production.  Taken together with prior translational studies in the setting of human 
infections, my present results suggest that human clinical studies in the setting of cancer 
and infectious disease should consider not only the overall precursor frequency of 
responsive T cells, but also differentiation stage, polyfunctional capacity (especially that 
of IFNγ /IL-2 co-production) or both.  Additionally, my results confirm that assays that 
measure IFNγ alone (including ELISPOT assays) will measure cells across the memory 
spectrum and may significantly underestimate the precursor frequencies of antigen-specific 
CD8+ T cells, especially those at later stages of the maturation spectrum. 
While studies like this one cannot directly confirm mechanisms operative in vivo, my 
results suggest that late memory CD8+ T cells that are abundant producers of MIP-1β, MIP-
1α and RANTES may have a unique functional role in human immune responses.  It is 
known that CCR5 up-regulation occurs with T cell activation (271), raising the possibility 
that late memory (M2 and M3) cells may have an autocrine or paracrine role in regulating 
immune responses.  Indeed, Wherry, Ahmed and colleagues (272) demonstrated 
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upregulation of MIP-1β and MIP-1α mRNA in a murine model, and suggested that 
chemotactic properties of murine CD8+ exhausted cells might “sound the alarm”.  
Consistent with this hypothesis, MIP-1β, MIP-1α and RANTES are potent chemotactic 
factors, inducing migration of monocytes and macrophages to the site of local elaboration.  
This raises the possibility that the activation of late memory CD8+ T cells (especially those 
specific for CMV and other herpes viruses that reside mostly in late memory stages) may 
serve as important attractors of cells capable of clearing debris and magnifying antigen 
presentation locally.  
My analysis of CMV-specific T cells confirmed the results of other studies 
demonstrating the abundance of later memory cells (i.e., M2 and M3 cells) within this 
antigen-specific population.  In contrast to my expectation that the most abundant product of 
CMV-specific T cells would be either IFNγ or TNFα, which have been most commonly 
utilized as markers of antigen-specific T cells, I found that MIP-1β was by far the most 
abundant cytokine produced by CD8+ CMV-specific T cells stimulated ex vivo.  Besides 
cells producing MIP-1β alone, I found fairly robust numbers of cells producing MIP-1β in 
conjunction with effector cytokines, including IFNγ/TNFα/MIP-1β, IL-2/IFNγ/TNFα/MIP-
1β, and IFNγ/MIP-1β were observed.  These data suggest that MIP-1β  may actually be a 
more sensitive marker than IFNγ  for the detection of CMV-specific T cells, and that 
conventional approaches (e.g., CFC or ELISPOT assays based on IFNγ  detection alone) 
may significantly underestimate the frequency of CMV-specific T cells.  This is relevant 
for clinical studies of CMV immunity in humans, and similar rules might apply to other 
disease settings and pathogens. 
This dissertation also demonstrated the differential expression of ERK1/2 and its 
functional consequence in human CD8+ T cell maturation subsets.  Although there have 
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been several studies examining the molecular signature of T cell maturation subsets and how 
genetic modulation might dictate T cell memory maturation (80, 119-121), few studies 
demonstrated a direct link to individual proteins determining functional heterogeneity 
including IL-2 production in human CD8+ T cell maturation subsets.  Moreover, none of 
studies highlighted human late memory CD8+ T cells in humans, in part due to technical 
limitations such as (a) limited cell number (b) low viability in liquid culture (c) difficulty 
manipulating gene expression.  By overcoming these limitations, I found that ERK1 is 
highly down-regulated in human late memory CD8+ T cells and that ERK1 down-regulation 
leads to poor production of IL-2 in human late memory CD8+ T cells.  These findings 
suggest that loss of ERK1 expression is a more accurate marker to delineate human late 
memory CD8+ T cells than classical surface markers and that ERK1 expression dictates 
functional heterogeneity in human CD8+ T cell maturation subsets. 
Adoptive transfer of virus-specific T cells isolated and expanded from a healthy 
donor, has been shown to be one of the potential therapeutic modalities against human viral 
infections in allogeneic SCT recipients (273-275).  Based on the relationship between 
polyfunctionality in T cells and virus control, as described in Chapter 1, adoptive transfer of 
polyfunctional T cells may be critical for a successful immunity against pathogens.  One 
recent study demonstrated that the reintroduction of CD28 in CD28- human CD8+ T cells 
increased IL-2 production (276).  My data suggest that polyfunctionality could be 
reconstituted in late memory CD8+ T cells by augmenting ERK1 expression by 
introduction of the gene with a constitutive promoter, leading to a strategy for optimal 
adoptive transfer to control viral reactivation in the allogeneic SCT setting. 
At the end of this dissertation, a novel therapeutic approach to reduce GVHD was 
introduced based on the observation suggesting that ERK1/2 phosphorylation differs in T 
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cell maturation subsets.  For the last years, small molecular inhibitors or monoclonal 
antibodies have been used to modulate immune function in humans.  Of many available 
drugs (Cyclosporin A, tacrolimus, steroids etc.), Sirolimus (Rapamycin) has recently been 
used as an immunosuppressive drug in SCT.  Recent studies suggest that Sirolimus has 
potentiating effects on CD4+CD25+ Tregs (277-279), and that activated conventional 
CD4+CD25- T cells become highly sensitive to Sirolimus, while Sirolimus rarely induces 
apoptosis in CD4+CD25+Tregs (277).  I hypothesized that differential phosphorylation of 
ERK1/2 reflects its functional utility in human T cell maturation subsets.  I demonstrated 
that the MEK inhibitor, U0126 suppressed cytokine production in T cells in a stage-
dependent manner, and that U0126 efficiently suppressed alloreactive T cell proliferation 
while sparing CMV-specific T cell responses and preserving TGFβ production in Tregs.  
This novel concept provides a better rationale to selectively inhibit undesired inflammation 
(GVHD) induced by early stage T cells (naïve and M1) and spare desired immune 
function by later stage memory T cells (M2, M3) (protective immunity against viral 
reactivation) in allogeneic SCT.  These results suggest that it may be more practical to find 
more selective targets and manipulate T cell subsets in vivo, to reduce GVHD and restore 
protective immunity, than to adoptively transfer ex vivo expanded T cell subsets.  
In conclusion, my studies establish the relationship between functional heterogeneity 
and molecular signature in human CD8+ T cell maturation subsets (Figure 31 and Table 2).  
I demonstrated in this dissertation that a) human late memory CD8+ T cells have a distinct 
cytokine production signature characterized by prolific production of MIP-1β (and other CC 
chemokines) and poor production of IL-2; b) These functional characteristics result from 
ERK1 down-regulation; c) ERK1 expression is a superior marker to define polyfunctional 
memory CD8+ T cells.  Moreover, these findings can be translated into important clinical 
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settings a) by reintroducing polyfunctionality in late memory CD8+ T cells by reexpressing 
ERK1 via genetic or pharmacological approaches, and b) by suggesting more rational and 
selective strategies to inhibit GVHD while relatively sparing pathogen-specific memory 
cells in allogeneic SCT recipients. 
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Figure 31. Functional (lack of IL-2 production) and molecular (loss of ERK1) 
markers are best to define late memory CD8+ T cells.  Summary of the relationship 
between functional heterogeneity and molecular signature in human CD8+ T cell 
maturation subsets and the rationale for selective inhibition based on differential 
expression of MAP kinases. 
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